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The ability to modulate protein function using exogenous small molecules is a 
longstanding goal in chemical biology. Selective activation or inhibition of a particular 
protein function can help elucidate crucial molecular mechanisms and enables important 
advances in cell biology. Small-molecule controlled molecular systems also possess 
tremendous value in bioengineering and biomedical applications: activation of protein 
function allows the construction of protein switches and biosensor proteins, whereas 
inhibition of protein function contributes to the development of novel therapeutic agents. 
The discovery of small-molecule modulators of function is greatly aided by 
computational modeling methodologies. By utilizing structural information obtained 
through X-ray crystallography or NMR spectroscopy, these tools allow efficient and 
affordable examination of large small-molecule databases and provide quantitative 
evaluation of the likelihood that a given protein-ligand interaction occurs. Advances in 
computer algorithms and hardware development continue to accelerate and scale up the 
computation and lower the cost of this discovery process. 
The primary focus of this thesis is the development of structure-based computer-
aided methodologies for designing small-molecule modulators of protein function. To 
this end I explored two parallel paths, one to study activation and one to study inhibition 
of protein functions. Taken together, my work aims to not only apply rational design 
strategies to specific proteins, but also demonstrate their general applicability. 
The first project, focused on activation of protein function, is built on an approach 
developed by our laboratory that designs a de novo allosteric binding site directly into the 
catalytic domain of an enzyme. This approach achieves modulation of function by a 
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novel “chemical rescue of structure approach”: a tryptophan-to-glycine mutation disrupts 
local structure and induces conformational changes that distort the geometry at the active 
site; the subsequent binding of exogenous indole then reverts this conformational change 
and restores the native enzyme structure. The main challenge of generalizing this 
approach, however, is the difficulty of rationally designing analogous conformational 
changes in other proteins. It is therefore important to study the possible mechanisms that 
can be utilized by chemical rescue of structure. Through collaborative and 
multidisciplinary efforts, we find that the switchable proteins built via the chemical 
rescue of structure are frequently controlled indirectly by modulating protein stability, 
rather than discrete conformational changes. Since energetic evaluation of protein 
stability is far more tractable than designing and/or predicting allosteric conformational 
changes, this finding demonstrates how chemical rescue of structure can be applied to 
other systems for building a variety of new protein switches. 
To further generalize the applicability of chemical rescue of structure, I sought to 
extend it to include multiple amino acids, rather than just one. I chose ChxR, a 
homodimeric response regulator in Chlamydia, as the model protein to examine the 
feasibility of this strategy. I mutated a pair of tryptophans at the dimer interface to 
glycine in order to disrupt the dimerization of ChxR. To enable the subsequent functional 
rescue, I used the removed structural elements as a template for ligand-based virtual 
screening and discovered a set of candidate small molecules that mimic the three-
dimensional geometry and chemical properties of the removed chemical moieties. 
Biophysical characterization of these compounds suggests that the majority of them 
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selectively bind to the engineered ChxR variant. This observation shows promises in 
extending this generalized design strategy to allow alternate activating ligands. 
In parallel to these efforts I carried out studies aimed at inhibition of protein 
function, as exemplified by my project that uses small molecules to disrupt a protein-
RNA interaction. Conventional methods of inhibitor design mostly target RNA-
processing enzymes and cannot be generalized to the majority of RNA-binding proteins 
(RBPs). I contributed to the development of a general strategy of designing competitive 
inhibitors targeting RBPs. This method involves identifying “hotspot pharmacophores” 
from the protein-RNA interaction and using it as a template in ligand-based virtual 
screening. To evaluate the performance of this approach, my collaborators and I applied 
it to Musashi-1 (Msi1), a protein that upregulates Notch and Wnt signaling pathway and 
promotes cell cycle progression. Our “hotspot mimicry” approach led us to discover 
compounds that match the hotspot pharmacophore, and thus enabled the development of 
novel inhibitors to the Msi1/RNA interaction that we validated in both biochemical and 
cell-based assays. This approach extends the “hotspot” paradigm from protein-protein 
complexes to protein-RNA complexes, and helps establish the “druggability” of RNA-
binding interfaces. It is the first example of a rationally-designed competitive inhibitor 
for a non-enzymatic RNA-binding protein. Owing to the simplicity and generality, I 
anticipate that the hotspot mimicry approach may lead to the identification of inhibitors 
of other protein-RNA complexes, which in future may serve as starting points for the 
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Chapter I.  
Introduction 
The interaction between proteins and small-molecule ligands is a fundamental 
molecular phenomenon. The binding of a small molecule can result in the selective 
modulation of protein function, which in turn can induce many important biological 
processes (1-4). Thus, the ability to systematically manipulate protein function with small 
molecules is highly desirable and in great demand in many facets of biological research. 
In the realm of fundamental biological studies, the selective activation or inhibition of 
protein function by small molecules has helped unravel the mechanism of many 
important biological processes (4-7). From a biotechnological perspective, small 
molecule-directed activation of engineered proteins can enable the development of 
biosensor proteins (8, 9) and genetic circuits (10); inhibition of protein activity by a small 
molecule, meanwhile, can serve as an indispensable method for prevention and treatment 
of diseases (11-13). 
Rational design of selective small-molecule modulators relies on structural 
insights, typically gained from X-ray crystallography or NMR spectroscopy. 
Computational tools and methodologies can further utilize the structural information and 
accelerate the design and identification processes. Together, this structural-based 
computer-aided design paradigm provides great robustness and generality for 
systematically designing protein structures, functions and interactions, and has enabled 
development of various small molecule modulators in different biological systems. 
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 “Turning on” Function - Designing Protein Switches and Biosensor Proteins 
The use of small molecules to selectively activate the function of engineered 
proteins gives rise to the construction of protein switches and biosensor proteins that 
serve as powerful chemical biology tools. In cell biology, protein switches have been 
applied to control various cellular processes, ranging from cell morphology to 
reprogramming cellular signaling pathways (2, 4, 14-16). Biosensor proteins have also 
resulted in a plethora of practical applications, such as detecting chemicals in food or the 
environment (17). 
Conventional Approaches 
The conventional strategies of engineering small-molecule dependent activity into 
proteins utilize allosteric protein domains that naturally bind to specific small molecules 
as the starting points. The conformational change induced by small molecule binding is 
coupled to the activation of the same or a separate domain. Catalytic domains are 
commonly chosen since the enzymatic reaction can amplify a single event of small 
molecule binding to the catalysis of multiple molecules of fluorescent or colorimetric 
products, allowing a more sensitive and quantitative detection of the analyte. 
Allosteric changes induced by small molecule binding can be relayed to increase 
catalytic activity via several methods (18): domain insertion is one such strategy that 
entails fusing the allosteric domain to a separate catalytic domain (19, 20). To achieve 
optimal spatial arrangement of two domains and preserve their native structures, circular 
permutation is frequently used to create multiple positions at which the guest domain can 
be inserted into the host domain. Successful designs can transduce the structural change 
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from the allosteric domain to the catalytic domain and modulate its activity. A different 
strategy couples small molecule binding to the correct assembly of enzyme structures: the 
allosteric domain is placed in the middle of the catalytic domain and separates it into two 
inactive halves. The allosteric changes upon small molecule binding, in selected cases, 
can bring the two halves to close proximity and lead to the assembly of active enzymes 
(21). A closely related approach utilizes protein splicing and constructs an inactive intein 
fragment by inserting an allosteric domain to intein (6). The engineered intein module is 
then inserted into a catalytic domain and inactivates it. The binding of small molecule 
activates the intein activity so that it self-cleaves out of the catalytic domain, which 
ultimately restores enzymatic activity. In addition to fusing separate allosteric domain 
and catalytic domains, de novo catalytic function can be directly engineered into an 
allosteric domain. However, this strategy is extremely limited with respect to the protein 
system, and to date only one successful application of this approach has been reported 
(22). 
The main challenge for these strategies, though, is the difficulty associated with 
predicting the detailed mechanism by which small-molecule binding modulates protein 
activity. Computational approaches are limited by the inaccuracies in biophysical 
representation of the molecular interactions and the complexity of conformation space. 
For this reason, these conventional approaches usually require the screening of multiple 
domain arrangements and various linker compositions to identify the optimal spatial 
arrangements that lead to allosteric regulation of enzyme activity upon small molecule 
binding. 
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Chemical Rescue of Structure 
Rather than using a natural allosteric transition, small molecule-dependent 
function can be de novo engineered into a protein domain that is not naturally allosteric. 
This entails constructing inactive protein variants, typically via single-point mutations; 
the subsequent addition of exogenous ligand that complements the removed structural 
elements can then restore the missing active-site moiety, and in turn regain the function. 
This de novo method is generally referred to as “chemical rescue” (23). The existing 
examples mainly focused on mutations at enzyme active sites and most notably used to 
rescue the function of a Src kinase variant in living cells (24). However, the chemical 
rescue of enzyme active sites often occurs through unanticipated mechanisms: in the Src 
kinase example, the arginine-to-alanine variant is most effectively rescued by imidazole, 
rather than guanidinium, which is the intuitive structural complement of the deleted 
chemical group. 
Inspired by the observation that internal cavities caused by mutations can 
sometimes be complemented by the binding of hydrophobic small molecules (25), our 
laboratory developed a different paradigm of chemical rescue, termed “chemical rescue 
of structure” (26). This method seeks to indirectly activate protein function by mutating 
residues at a separate buried site, instead of immediately at the active sites. A buried 
tryptophan residue is typically selected and mutated to glycine, with the expectation that 
the removal of the tryptophan sidechain may result in a more substantial energetic 
destabilization than other amino acids due to its size and hydrophobicity. 
When using this method, we seek to identify a buried tryptophan sidechain that 
serves as a structural “buttress”, in that it supports the structural integrity of the nearby 
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protein architecture. The deletion of a buttressing tryptophan can potentially result in 
various structural consequences, ranging from a discrete conformation change to varying 
extents of protein unfolding and leads to the loss of protein function. The subsequent 
restoration of the buttress by the addition of exogenous indole, which complements the 
deleted tryptophan sidechain, can reinstate the original protein structure, and thus 
reactivate protein function. Chemical rescue of structure has been applied to β-
glycosidase and led to the construction of an indole-controlled enzyme switch in living 
cells (26). 
Chemical rescue of structure is not limited to catalytic domains; in fact, it has also 
been successfully applied to GFP and multiple essential proteins from E.coli (27). 
Another natural extension of chemical rescue of structure is mutating multiple amino 
acids, instead of a single tryptophan. In this scenario, deleting a constellation of atoms 
from neighboring hydrophobic sidechains creates the larger buried cavity, and the 
binding of small molecules that resemble the structural geometry and chemical property 
of the removed chemical groups can potentially restore the protein structure and function. 
 “Turning off” Function - Designing Small Molecule Inhibitors 
Discovery and characterization of small molecules that inhibit cellular function of 
specific proteins is an active research area that has received great attention from the 
scientific community. In basic cell biology, small molecule inhibitors that can permeate 
the cell membrane provide a means of hindering the normal function of a specific protein 
target and are indispensable tools for elucidating the intracellular role of that protein (28, 
29). In biomedical applications, identifying small molecule inhibitors and transforming 
them into potent lead compounds are essential activities in modern drug discovery. These 
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small molecules frequently serve as invaluable starting points for developing novel and 
selective therapeutic agents that lead to the repression of aberrant cellular functions by 
mutated or dis-regulated protein targets in various diseases (13, 30). 
Conventional Strategies 
High-throughput screening (HTS) is a method for discovering small molecule 
inhibitors and/or optimizing lead series (31, 32). HTS entails testing a library of 
chemically synthesized or naturally occurring small molecules, and enables the rapid 
identification of active compounds for a protein target via biochemical or cellular assays. 
Using robotics and data processing technologies, it is possible to test libraries containing 
millions of compounds. However, HTS is generally very expensive and time consuming 
to perform, and the success rate of HTS is limited by the compounds in theses selected 
libraries, which are biased towards chemotypes that have proven successful against 
popular therapeutic targets, and thus may not be suitable for different classes of protein 
targets (33). 
For these reasons, traditional HTS has been complemented by structure-based 
computer-aided methodologies in recent years, which provides a rational means to design 
and/or identify small molecule inhibitors. Structure-based approaches rely on the X-ray 
crystallographic or NMR-based structures of a protein target to rationally design small 
molecules that are likely to bind and inhibit the protein function. Computational tools and 
algorithms often aid the discovery process to optimize potential hit compounds identified 
from HTS or structure-based methods, or to screen for novel inhibitors from larger virtual 
libraries. 
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Virtual screening can be performed using two general paradigms: ligand-based or 
structure-based screening (34). Ligand-based methods collectively consider the structures 
of diverse small-molecule ligands that are known to bind to the protein targets, and 
extract crucial features that the new compounds need to possess. These structural features 
are included in models known as “pharmacophore” and are compared to a library of 
candidate small molecules to identify the ones compatible with the pharmacophore model. 
In contrast, structure-based screening does not require the complex structure of protein 
and small-molecule ligand. This methodology involves docking different conformations 
of candidate small molecules into postulated binding sites on protein. The likelihood of 
ligand binding is then predicted by score functions that model molecular interactions and 
estimate binding affinities. 
Traditional vs. Non-Traditional Drug Targets 
The primary targets in traditional inhibitor discovery are protein receptors that 
naturally bind to small-molecule ligands. These targets include signaling proteins whose 
functions are regulated by small molecules, and enzymes using small molecules as 
substrates (33). In recent years, however, increased attention has been shifted to proteins 
interacting with other types of macromolecules, such as nucleic acids or other proteins 
(35, 36). These interactions are crucial to a wide variety of biological processes, and 
therefore offer more potential drug targets for therapeutic intervention. 
These non-traditional interactions remain enticing, but extremely difficult, targets 
for developing small molecule inhibitors. The rare instances of small molecules that bind 
to the non-traditional interfaces result in the lack of starting points for inhibitor 
development. Compared to the deep and hydrophobic binding pockets in traditional 
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targets, the general flatness of the interface further complicates the problem, as it is 
difficult to identify druggable sites on this type of interface (37).  
These challenges imply that preexisting small molecule libraries and 
computational methodologies, which were developed and parameterized for traditional 
targets, may not be appropriate for these non-traditional targets. Recently, a systematic 
examination from our laboratory revealed the differences between inhibitors for 
traditional drug targets and protein-protein interactions (PPI) (33). Due to the flat 
interface, inhibitors for PPI are less buried than the traditional counterparts, and owing to 
this reduce ligand efficiency more atoms are required to achieve a given potency. Small 
molecules included in the screening libraries have been preselected to cater to the 
traditional classes of protein targets, and therefore these libraries may be ill-suited for 
non-traditional proteins in ligand-based screening. The systematic differences between 
these two classes of targets also lead to complications in structure-based virtual 
screening. The parameters in popular docking tools are trained and optimized against the 
deep binding pockets from traditional targets. Therefore, their performance deteriorates 
when dealing with the relatively exposed binding modes of non-traditional inhibitors (11, 
37). 
Fortunately, advances in protein-protein interactions provide a promising strategy 
for designing inhibitors to non-traditional targets. In protein-protein interactions, binding 
affinity is not evenly distributed over the binding interface. Rather, a small cluster of 
“hotspot” residues contribute to most of the binding energy (38-40). This observation has 
naturally led to the idea of using these “hotspot” interactions as the templates in drug 
discovery (11, 40, 41): small molecule inhibitors can be rationally designed by 
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mimicking the structural geometry and chemical properties of “hotspot” residues. 
Retrospective inspection reveals that certain inhibitors identified via irrational HTS 
actually resemble the structure of a cluster of “hotspot” residues at the interaction 
interface, which validate the feasibility of this “hotspot” mimicry approach (42, 43). To 
predict or identify the hotspot residues in PPI, a number of computational methods, along 
with the experimental alanine scanning, have been developed (40, 44, 45), and enabled 
the development of inhibitors for several PPI targets (43, 46-48). 
Targeting Protein-RNA Interactions 
Protein-RNA interactions represent a class of non-traditional targets that offer 
great promise and opportunity for drug development. RNA-binding proteins (RBPs) bind 
to single or double stranded RNA in cells and play crucial roles in diverse cellular 
processes. RBPs participate in post-transcriptional control of RNAs, which is one of the 
major ways of gene regulation during development (49, 50). The post-transcriptional 
regulation occurs at many different stages in RNA metabolism, including splicing (51), 
polyadenylation (52), mRNA stability (53), mRNA localization (54) and translation (55), 
and these regulatory functions are achieved through either the nucleic acid processing by 
RNA-binding enzymes (such as RdRPs and reverse transcriptase) (56, 57) or the specific 
RNA-binding by non-enzymatic RBPs (such as HuR and Musashi 1) (58-60). Due to the 
versatile functions carried out by RBPs, modifying and controlling their interactions with 
the cognate RNAs is an essential means for elucidating the mechanisms of important 
biological processes, and developing therapeutic interventions of various diseases. 
To date, there exist only limited examples of rationally designed small molecule 
inhibitors that target protein-RNA interactions. Based on the design strategies, they can 
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be categorized into three general classes: The first class contains nucleoside analogues 
(eg. NRTIs for HIV), which mimic the chemical structures of natural-occurring 
nucleosides (61-63). They can competitively bind to the orthosteric sties and interfere 
with the synthesis of nucleic acids through diverse mechanisms (64-66). The main 
advantage of nucleoside analogues is the extremely straightforward design scheme. 
However, nucleoside analogues alone provide only inadequate binding affinities due to 
limited sizes of compounds. The implication is that the spontaneous binding and correct 
functioning of nucleoside analogues require the coupling to the energy provided by 
enzymatic reactions. Therefore, their usage is strictly confined to nucleic acid-processing 
enzymes and cannot be generalized to non-enzymatic instances. Furthermore, nucleoside 
analogues are not specific to the designed targets due to the close resemblance to 
naturally occurring nucleosides and the off-target binding can lead to severe side effects 
(67, 68). The second class consists of allosteric inhibitors which bind to secondary sties 
on the protein targets and shift the conformation ensemble towards an inactive state (eg. 
NNRTIS for HIV) (63, 69, 70). They can be used to target both enzymatic and non-
enzymatic instances of RBPs and deliver desirable binding affinity and selectivity. The 
main disadvantage, though, is that the rational design of allosteric inhibitors is extremely 
difficult, as it entails the identification of both allosteric sites and small molecules that 
bind to such sites and transition the protein into inactive conformations. The third class of 
inhibitors are RNA-binding small molecules originated from docking small molecules 
onto RNA structures, instead of RBPs (71, 72). This strategy also provides a rational way 
of designing inhibitors targeting non-enzymatic RBPs, but the binding of small molecules 
may affect the normal functioning of the RNAs. In addition, without the structural 
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information of bound RNAs there is no guarantee that the targeted RNA conformation 
cannot bind to the protein partner. 
The non-traditional nature of protein-RNA interactions may most likely be the 
cause for the limited success in previous rational designs. RBPs have naturally evolved to 
bind to RNAs, in contrast to the traditional protein targets that bind to small molecules 
(33). This difference poses challenges to ligand-based virtual screenings because of the 
lack of templates as the starting points. There exists few instances of natural small 
molecules known to bind at protein–RNA interfaces (except for nucleotides) and the 
natural binding partners (cognate RNA) are too large to guide the design of small 
molecule inhibitors and cannot be used as a whole to infer their druggability (11, 33). 
Structure-based virtual screening (i.e. docking) is also expected to be troublesome when 
applying to the shallow and polar interfaces of the non-traditional interactions (11, 37). 
Computational Tools 
Rapid Overlay of Chemical Structure 
Rapid overlay of chemical structure (ROCS) is employed in ligand-based virtual 
screening to identify small molecule conformers that mimic the 3D geometry and 
chemical properties of the template. ROCS is a ligand centric 3D method that aligns two 
compounds by their similarity in shape (73). ROCS can be used to match (search) the 
shape of a large collection of compounds in a database to a query molecule. The input 
and query molecule are aligned and optimized very rapidly using atom-centered Gaussian 
functions to maximize the overlap of volume between them. The similarity of two 
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The I terms are self-volumes of each molecule, while the O term is the overlap 
between two molecules. 
Along with shape matching (ShapeTanimoto), ROCS also includes 
pharmacophoric features (ColorTanimoto), such as hydrogen bond donor, acceptor, and 
aromatic rings, to score the alignment. Previous studies shows that the combination of 
both shape and color score (TanimotoCombo) gives better enrichment (74-76).  
Rosetta Software Suite 
The structure evaluation and prediction in my studies have been primarily carried 
out using the Rosetta software suite (77). Rosetta is a popular object-oriented software 
package that provides versatile and robust tools for predicting and designing protein 
structures, and their interaction with other macromolecules. 
 The general strategy of Rosetta is to capture the natural variation observed in 
protein structures. Protein systems can be described and modeled using sets of degree of 
freedoms (DOFs), such as φ/ψ/ω/χ angles in protein folding and translation/rotation in 
docking. A given conformational manipulation results in changes in the DOF space, 
which in turn determine the coordinates of atoms in 3D Cartesian space. The energetic 
consequence of such structrual manipulations can be evaluated by the Rosetta energy 
function using the Cartesian coordinates of atoms. In computational modeling of protein 
structures, this workflow of "DOFs space (torsion space) à Cartesian space à Energy" 
is applied for a large number of iterations to explore the relevant conformational space 
and locate the conformation(s) with the lowest energy. Minimization methodologies, such 
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as Monte Carlo simulation and gradient descent, are used in the process to guide the 
trajectories of the simulation. 
In Rosetta, a molecular system is modeled by an object called Pose. The Pose 
object represents a certain state of a molecular system, and contains all the structural 
information that is required to completely describe the system in both torsion and 
Cartesian space. In addition to the storage of structural information, the Pose object 
contains two essential components that facilitate the modeling on the molecular system: 
Conformation and Energy. Upon a structural movement, the Conformation 
component updates the DOFs in the torsion space and translates the changes to the 
Cartesian coordinates. Given an updated conformation, the Energy component is 
responsible for evaluating and storing the energy of the current structure. 
Structural manipulations in Rosetta are achieved by Mover objects. The Mover 
objects operate on Pose objects and apply different types of conformational 
perturbation by instructing the update of the torsion space. Mover objects allow a variety 
of manipulations to the protein conformation, ranging from the perturbation of backbone 
torsion angle to the minimization of structures. In a single iteration of modeling, these 
Mover objects can either executed for multiple cycles or be combined together to 
perform a composite modification. The conformational search space can be limited and 
controlled using the MoveMap object, which specifies the DOFs that need be held rigid 
during simulation. 
Rosetta score function evaluates the energy of Pose objects. The Rosetta score 
function is a weighted sum of independent energy terms. These energy terms captures the 
likelihood of a particular conformation, as well as the fitness of sequence given a protein 
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conformation. Over 20 energy terms are available in the score function, and they mainly 
describe van der Waals attractive/repulsive interactions, solvation energy and hydrogen 
bonding and electrostatic energy. Each energy component is calculated by a certain 
“energy method”. For example, the van der Waals interactions are modeled by Lennard-
Jones potential. The attractive and repulsive components are separated with different 
weights. The solvation energy is described by Lazaridis–Karplus solvation free energy. 
The user can customize the score function by either adding additional energy terms or 
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Chapter II.  
The Designability of Protein Switches by Chemical Rescue of Structure:  
Mechanisms of Inactivation and Reactivation 
Abstract 
The ability to selectively activate function of particular proteins via 
pharmacological agents is a longstanding goal in chemical biology. Recently, we reported 
an approach for designing a de novo allosteric effector site directly into the catalytic 
domain of an enzyme. This approach is distinct from traditional chemical rescue of 
enzymes in that it relies on disruption and restoration of structure, rather than active site 
chemistry, as a means to achieve modulated function. However, rationally identifying 
analogous de novo binding sites in other enzymes represents a key challenge for 
extending this approach to introduce allosteric control into other enzymes. Here we show 
that mutation sites leading to protein inactivation via tryptophan-to-glycine substitution 
and allowing (partial) reactivation by the subsequent addition of indole are remarkably 
frequent. Through a suite of methods including a cell-based reporter assay, computational 
structure prediction and energetic analysis, fluorescence studies, enzymology, pulse 
proteolysis, x-ray crystallography and hydrogen-deuterium mass spectrometry we find 
that these switchable proteins are most commonly modulated indirectly, through control 
of protein stability. Addition of indole in these cases rescues activity not by reverting a 
discrete conformational change, as we had observed in the sole previously reported 
example, but rather rescues activity by restoring protein stability. This important finding 
will dramatically impact the design of future switches and sensors built by this approach, 
since evaluating stability differences associated with cavity-forming mutations is a far 
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more tractable task than predicting allosteric conformational changes. By analogy to 
natural signaling systems, the insights from this study further raise the exciting prospect 
of modulating stability to design optimal recognition properties into future de novo 
switches and sensors built through chemical rescue of structure. 
Introduction 
Important advances in cell biology have been enabled through the ability to 
selectively activate proteins involved in key processes (5, 7, 15, 78-81). We recently 
described an approach for introducing allosteric control into enzymes via a strategy 
termed “chemical rescue of structure” (26). This strategy entails introducing one or more 
cavity-forming mutations into a protein core at “buttressing” locations, i.e. where specific 
sidechains are critical for maintaining the structural integrity of the active site. Deletion 
of these “buttressing” residues leads to distortion of the active site geometry, and 
accordingly loss of enzyme activity. The subsequent addition of an exogenous compound 
that matches the deleted moiety is then expected to restore the “buttress” by binding in 
the cavity, and thus restore protein structure and activity. 
Our previous studies (26) focused on β-glycosidase from S. solfataricus as a 
model enzyme. We introduced a tryptophan-to-glycine mutation (W33G) at a site close to 
(but distinct from) the active site, and found the ratio kcat/Km for this mutant to be about 
730-fold worse than that of the wild-type enzyme. Upon solving the crystal structure of 
this mutant, we found that a very local conformational change distinguished it from the 
wild-type structure: a single nearby active site residue had shifted away from the active 
site to fill the cavity produced by the mutation. The change in position of this active site 
residue led to a loss of contact with the substrate, explaining the loss of function. We then 
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found that exogenous indole could be used to completely restore activity to the mutant, 
with both kcat and Km reaching the corresponding values of the wild-type enzyme. The 
crystal structure of the mutant enzyme in complex with indole revealed that indole 
occupied exactly the cavity created by the mutation. This in turn perfectly restored the 
active site geometry, explaining the complete rescue of enzyme activity. 
In contrast to chemical rescue of structure, most approaches for building ligand-
dependent activity into enzymes have involved fusing a gene encoding some naturally-
occurring allosteric “binding domain” (for the desired ligand) into a gene encoding some 
naturally-occurring “output domain” (for the desired activity) (82). By using screens or 
selections to sift through the large number of potential insertion points and linkers, these 
fusions of existing protein domains have led to a variety of synthetic “switchable” 
proteins that are activated through allostery by the binding of an effector ligand (1, 15, 
83-86). The chemical rescue of structure approach is unique in that it introduces a ligand-
binding site directly into the “output domain,” rather than rely on allosteric coupling to a 
separate “binding domain.” This alleviates the need for a naturally-occurring allosteric 
binding domain as a starting point, but instead requires that ligand binding alters 
intradomain function. 
In the β-glycosidase example described above, the structural consequences of the 
cavity-forming mutation were indeed transduced to the active site, leading to loss and 
subsequent rescue of function. However, identifying cavity-forming mutations that 
induce analogous conformational changes in other proteins represents a key challenge in 
building further de novo switches and sensors by chemical rescue of structure. Here, we 
seek to explore the general considerations that make this approach possible. In particular, 
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we aim to address the following questions: How frequently does a single WàG cavity-
forming mutation induce loss of function? How might one select sites that will lead to 
protein inactivation and reactivation by indole? And most importantly, must we explicitly 
tackle the challenge of modeling conformational changes resulting from cavity-forming 
mutations in order to predict sites at which chemical rescue of structure may be applied? 
Materials and Methods 
Plasmids and Cloning 
For the cI repressor assay, genes encoding the homodimeric protein targets were 
obtained from E.coli K12 MG1655 genome via PCR. The gene encoding the cI lambda 
repressor DNA-binding domain was acquired from lambda phage DNA. We cloned the 
N-terminal DNA-binding domain of cI (residues 1-132) into pth7035K (R6K origin and 
Kanamycin R). Driving the cI truncation was a constitutive promoter generated in-house. 
Additionally, at the C-terminus of the cI truncation we included a 6aa flexible linker. We 
then subcloned in amplicons of the genes encoding the homodimeric protein targets to 
generate cI–target gene fusions. A summary of the homodimeric protein targets is 
included in Table 2.1.  
To study dimerization of these target proteins, we engineered reporter cells 
containing the Pr promoter driving GFP expression. The Pr promoter segment was 
obtained from lambda phage DNA and was subcloned into pth7033C containing the 
ColE2 origin of replication and chloramphenicol resistance marker. The Pr reporter 
plasmid was transformed into E. coli DIAL strain JI (87). 
 20 
A plasmid containing the E.coli β-glucuronidase (β-gluc) gene was generously provided 
by Bret Wallace and Matt Redinbo (University of North Carolina). A plasmid containing 
the +5 GFP gene was generously provided by David R. Liu (Harvard University). 
+5 GFP is a 3-point mutant (G65T/R80Q/V206A) of superfolder GFP (88). Genes 
encoding β-gluc and +5 GFP were amplified using PCR. The DNA fragments were cut 
with the SspI restriction enzyme and cloned into a ligation-independent vector pTBSG1 
generously provided by F. P. Gao (University of Kansas). The final construct encodes an 
N-terminal 6xHis tag, a 17-amino-acid linker, and the gene of interest (β-gluc or +5 GFP) 
under control of a T7 promoter. 
Protein expression and purification 
Recombinant β-gluc and +5 GFP were expressed from a pET28a vector in E. coli 
Rosetta 2(DE3)pLysS cells at 15ºC overnight. The cells were resuspended in Lysis Buffer 
(50 mM Tris, 150 mM NaCl, 5 mM imidazole pH 8.0) and sonicated for 10 minutes 
(Fisher Scientific Sonic Dismembrator Model 100). The cell lysates were then 
centrifuged at 15,000g for 30 min. The β-gluc remained in the supernatant, which was 
purified by HPLC affinity chromatography with Ni-chelated Sepharose Fast Flow Resin 
(GE Healthcare), followed by a HiLoad 16/60 Superdex 75 gel filtration column (GE 
Healthcare). 
Point mutations were introduced using the QuikChange methodology (Stratagene), and 
mutant proteins were purified as described for the corresponding wild-type (WT) protein. 
All protein concentrations were determined with reference to bovine albumin standards 
using Bradford assays. 
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cI repressor reporter assay 
Expression plasmids for gene fusions of cI with the target protein (wild-type or 
WàG mutant) were transformed into the reporter JI PrGFP E.coli strain, along with the 
cI wild-type (constitutive dimer) as a control. Colonies were picked in triplicate, 
inoculated in 1 mL 2YT Kan/Cam media and grown to saturation at 37˚C. The following 
day, 1 µL of saturated culture from each sample was seeded into 999 µL of 2YT 
Kan/Cam media with or without 1 mM indole (final concentration). Cultures were grown 
to saturation at 37˚C, and 200 µL of each sample was transferred to a Costar 96-well flat 
black bottom plate for TECAN analysis. Final growth and fluorescence (RFU) time-point 
reads were taken at OD600nm and 481nm, respectively. All RFU data were normalized for 











Table 2.1: A summary of homodimeric E. coli proteins included in the reporter gene 
assay. 
 
Gene Activity of protein product PDB entry Number of Trp 
yeaZ unknown function (hypothetical protease) 1OKJ (89) 7 
orn exoribonuclease 2IGI (90) 4 
















Calculation of distance from mutation site to dimer interface 
For each dimeric protein target, the distance from the WàG mutation site to the 
dimer interface was defined to be the Euclidean distance between the Cα atom at the 
mutation site and the closest Cα atom on the other chain. Distances were calculated using 
PyRosetta (92). 
Rosetta refinement protocol and estimated stability differences 
Estimates of protein stability differences were computed out using the Rosetta 
macromolecular modeling suite (77). All calculations were carried out using svn revision 
54048 of the developer trunk source code. Rosetta is freely available for academic use 
(www.rosettacommons.org). 
The Rosetta command line used to carry out refinement simulations is as follows: 
relax.linuxgccrelease -s input_pdb –relax:fast –in:file:fullatom 
 
We generated the starting structure of each WàG mutant from the cI repressor 
assay by manually modifying of the wild-type PDB file: removing the sidechain atoms 
from tryptophan and changing the amino acid identity to glycine. During the simulation, 
this refinement protocol entails optimization of both backbone and sidechain degrees of 
freedom in a Monte Carlo search. 
We performed 1000 independent simulations for each mutant and computed the 
energy for each output structure. Energies for a given protein construct—whether the 
dimer interface energy or the total energy of the (dimeric) protein—were taken to be the 
average over the 100 lowest-energy output structures. From each of these averages we 
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subtracted the average value from analogous simulations of the corresponding wild-type 
protein. 
GFP fluorescence assays 
Fluorescence studies were carried out using protein concentration of 9.5 µg/ml in 
20mM Tris-HCl (pH 8.0), 20 mM NaCl, 5% DMSO (with or without 1 mM indole). 
GFP pulse proteolysis 
Subtilisin (P5380) was acquired from Sigma-Aldrich. Proteolysis experiments 
were carried out in 20mM Tris-HCl (pH 8.0), 20 mM NaCl, using 0.9 mg/ml of +5 GFP 
(wild-type, W57G, or W57A) and increasing concentrations of subtilisin. The protease 
inhibitor control experiment included 5 mM PMSF (phenylmethanesulfonylfluoride). 
Reactions were incubated at 37˚C for 1 hour.  
Band intensities were quantified using ImageJ (http://imagej.nih.gov/ij/). The gel 
image was converted to grayscale and the colors were inverted. Next, a strip of bands 
were selected in a rectangle and the intensity of each band in the region was computed 
using a built-in feature of ImageJ. 
GFP crystal structures 
A purified sample of the +5 GFP point mutant (W57G or W57A) concentrated to 
4.0 mg/mL in 100 mM NaCl, 20 mM Tris pH 8.0 was used for crystallization screening. 
All crystallization experiments were conducted using Compact Jr. (Emerald Biosystems) 
sitting drop vapor diffusion plates at 20˚C using equal volumes of protein and 
crystallization solution equilibrated against 75 µL of the latter. 
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For W57G, yellow crystals that displayed a prismatic morphology formed in one 
week from the IndexHT screen (Hampton Research) condition D6 (25% (v/v) PEG 3350, 
0.1 M Bis-Tris 5.5). Streak seeding was conducted which resulted in the production of 
higher quality crystals. Samples were transferred to a fresh drop composed of 75% 
crystallization solution and 25% PEG 400, and stored in liquid nitrogen. X-ray diffraction 
data were collected at the Advanced Photon Source beamline 17-ID using a Dectris 
Pilatus 6M pixel array detector. 
Intensities were integrated using XDS (93) and the Laue class analysis and data 
scaling was performed with Aimless (94), which confirmed that the highest probability 
Laue class was mmm and space group was likely P212121. The Matthew’s coefficient (95) 
indicated that the asymmetric unit contained four independent molecules (Vm=2.1 Å2/Da, 
40.7% solvent). Structure solution was conducted by molecular replacement with Phaser 
(96) using a previously determined structure of the superfolder GFP (PDB: 2B3P) as the 
search model. All space groups with 222 point symmetry were tested for the molecular 
replacement searches and the top solution was obtained for four molecules in the 
asymmetric unit in the space group P212121. Structure refinement and manual model 
building were conducted with Phenix (97) and Coot (98) respectively. TLS refinement 
(99) was incorporated in the later stages to model anisotropic atomic displacement 
parameters. Structure validation was conducted with Molprobity (100). 
For W57A, yellow crystals that displayed a prismatic morphology formed in 2–4 
days from various conditions in the Wizard 3&4 screen (Emerald Biosystems). Crystals 
obtained from condition H9 (40% (v/v) isopropanol, 0.1 M imidazole / hydrochloric acid 
6.5, 15% (w/v) PEG 8000) were used for data collection. Samples were transferred to a 
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fresh drop composed of 80% crystallization solution and 20% ethylene glycol, and stored 
in liquid nitrogen. Initial X-ray diffraction data were collected in-house at 93K using a 
Rigaku RU-H3R rotating anode generator (Cu-Kα) equipped with Osmic Blue focusing 
mirrors and an R-Axis IV++ image plate detector. Higher resolution diffraction data were 
collected at the Advanced Photon Source beamline 17-ID using a Dectris Pilatus 6M 
pixel array detector. 
Intensities were integrated using XDS (93) via the XDSAPP (101) interface. 
Indexing suggested a monoclinic C lattice with a=88.51 Å, b=46.43 Å, c=69.36 Å, 
β=123.4o. The Laue class analysis and data scaling were performed with Aimless (94) 
which confirmed that the highest probability Laue class was 2/m and space group C2. 
The unit cell was transformed to the non-standard body-centered setting I2 with a=69.36 
Å, b=46.43 Å, c= 76.69 Å, β=105.6o using the reindexing operator (-l, k, h+l). Structure 
solution was conducted by molecular replacement with Phaser (96) via the Phenix (102) 
interface using the in-house diffraction data scaled to 1.37 Å resolution. A previously 
determined structure of superfolder GFP (PDB: 2B3P) served as the search model. A 
clear solution for a single molecule in the asymmetric unit was obtained. Structure 
refinement using anisotropic atomic displacement parameters and manual model building 
were conducted with Phenix and Coot (98), respectively. Structure validation was 
conducted with Molprobity (100). 
Figures were prepared using the CCP4MG package (103). Relevant 
crystallographic data are provided in Table 2.3. The Cα RMSD for residues within 4 Å of 
the chromophore was computed using the following 21 residues: 44, 46, 61, 62, 63, 64, 
68, 69, 94, 96, 112, 121, 145, 148, 150, 165, 167, 203, 205, 220, 222. 
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Table 2.3: Crystallographic data for superfolder +5 GFP W57G refined to 1.6 Å 
resolution, and for +5 GFP W57A refined to 1.1 Å resolution. 
 
 W57G W57A 
Data Collection   
     Unit-cell parameters (Å, o) a=96.07, b=97.25, 
c=98.16 
a=69.36, b=46.43, c=76.69, 
β=105.6 
     Space group P212121 I2 
     Resolution (Å)* 48.03-1.60 (1.63-1.60) 44.02-1.10 (1.12-1.10) 
     Wavelength (Å) 1.0000 0.8265 
     Temperature (K) 100 100 
     Observed reflections 803,212 313,428 
     Unique reflections 121,582 93,517 
     <I/σ(I)>* 15.3 (2.0) 12.1 (1.9) 
     Completeness (%)* 100 (100) 98.3 (98.4) 
     Multiplicity* 6.6 (6.6) 3.4 (3.2) 
     Rmerge (%)*# 7.5 (95.5) 4.5 (48.9) 
     Rmeas (%)*^ 8.1 (104.5) 5.4 (67.6) 
     Rpim (%)*^ 3.1 (40.5) 2.9 (37.2) 
     CC1/2 *@ 0.999 (0.704) 0.999 (0.767) 
Refinement   
     Resolution (Å) 43.07-1.60 24.70-1.10 
     Reflections (working/test) 115,373/6,107 88,532/4,689 
     Rfactor / Rfree (%)& 15.5/18.2 13.4/14.6 
     No. of atoms (Protein/Water) 7,214/633 1,919/257 
Model Quality   
R.m.s deviations    
     Bond lengths (Å) 0.009 0.008 
     Bond angles (o) 1.075 1.278 
Average B-factor (Å2)   
     All Atoms 24.5 15.4 
     Protein 23.8 13.5 
     Water 33.1 29.0 
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     Coordinate error 
(maximum likelihood) (Å) 
0.16 0.10 
Ramachandran Plot    
     Most favored (%) 98.9 99.2 
     Additionally allowed (%) 1.1 0.8 
 
* Values in parenthesis are for the highest resolution shell. 
# Rmerge = ΣhklΣi |Ii(hkl) - <I(hkl)>| / ΣhklΣi Ii(hkl), where Ii(hkl) is the intensity measured for the ith 
reflection and <I(hkl)> is the average intensity of all reflections with indices hkl.  
& Rfactor = Σhkl ||Fobs (hkl) | - |Fcalc (hkl) || / Σhkl |Fobs (hkl)|; Rfree is calculated in an identical manner 
using 5% of randomly selected reflections that were not included in the refinement 
^ Rmeas = redundancy-independent (multiplicity-weighted) Rmerge (94). 
^ Rpim = precision-indicating (multiplicity-weighted) Rmerge (104, 105). 
@ CC1/2 is the correlation coefficient of the mean intensities between two random half-sets of 












Hydrogen-deuterium exchange and mass spectrometry 
Hydrogen–deuterium exchange experiments for β-gluc were carried out at a 
protein concentration of 0.5 µg/µL in 50 mM sodium phosphate, 100 mM sodium 
chloride, 10% ethanol, pH 7.4. Experiments were carried out the absence of indole, or in 
the presence of 5 mM indole. 
All deuterium exchange experiments were carried out by a LEAP HDX-PAL 
robot (LEAP Technologies, Carrboro, NC). The robot was used to mix 2 µL of protein 
solution with 40 µL deuterium exchange buffer, followed by the addition of 40 µL 
quench buffer after the desired labeling time. Deuterium exchange labeling times were: 
10 sec, 30 sec, 1 min, 2 min, 5 min, 20 min, 1 hour, and 12 hours. The deuterium 
exchange buffer was 50 mM sodium phosphate, 100 mM sodium chloride, with and 
without 5 mM indole in 90% D2O, 10% ethanol, pD 7.4. Undeuterated control samples 
were prepared using analogous buffers containing 90% H2O instead of D2O, at pH 7.4. 
All deuterium exchange buffers were kept at ambient room temperature. The exchange 
quench buffer was 0.75 M hydrochloric acid, kept at 1°C. Following the labeling, quench 
buffer was added to sample at a 1:1 volume ratio. Quenched samples were immediately 
injected onto a 100 µL loop prior to pepsin digestion and peptide separation. 
An isocratic pump flowed 0.1% formic acid at 0.2 mL/min through the sample loop to 
inject samples through an immobilized pepsin column, prepared in-house, for online 
proteolysis of labeled samples (108). Peptides were captured on a C12 trap, packed in-
house. A 4.5–40.5% acetonitrile gradient over 10 minutes was used to separate peptides 
on a 50 mm × 1 mm Ascentis Express ES-C18 column (2.7 µm particle size, 160 Å pore 
size, Supelco Analytical, Bellefonte, PA). All HPLC components were kept at 0°C to 
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reduce back-exchange. Eluted peptides were analyzed by TOF-MS (Agilent 
Technologies, Santa Clara, CA). HDExaminer (Sierra Analytics, Modesto, CA) was used 
to obtain average mass values for peptide spectra at each labeling time and for the 
undeuterated controls. 
Peptides were assigned by mapping the masses onto the protein sequence with a 
mass tolerance of +/- 10 ppm.  Peptides that had ambiguous assignments were not 
included in the analysis. 
Analysis of hydrogen-deuterium exchange and mass spectrometry data 
For each assigned peptide we computed the mass increase Δm at each time point. 
To compare data from different conditions (i.e. WT versus mutant, with or without 
indole), we divided the difference in mass increase at each time point (ΔΔm) by the 
number of exchangeable amide hydrogens to normalize for peptide length, and then 
averaged this value over all time points. This yielded a “normalized deuterium 
difference” for each peptide, NDD, that can range from -1 to 1. The normalized 
deuterium difference for a given residue in the protein sequence was taken to be the 
average NDD value over all peptides covering that residue. 
Determining what constitutes a statistically significant difference between two 
states of a single peptide requires uncertainty calculations provided by replicate sample 
analyses. A single standard deviation of ±0.14 Da for a replicated time point (i.e. a Δm 
measurement) with a 98% confidence interval of about ±0.5 Da has been reported in 
previous works (109, 110). The confidence interval appears to be unaffected by labeling 
time, peptide length, or mass difference caused by deuterium uptake (109). The ±0.14 Da 
standard deviation may be used to calculate a statistical significance threshold between 
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multiple datasets that contain all time points, ΣΔΔm, using the Student’s t-distribution. In 
a previous study (109), 5 time points were sampled to give a 98% confidence interval of 
±1.1 Da. Because of single trial sampling conducted for our study, we instead adopt the 
uncertainty from this previous study (109). If uncertainty and artificial triplicate sampling 
are applied to this work and are assumed to be similar to those of the previous study 
(109), the significance threshold would be about ±1.7 Da for the 9 sampled time points. 
Statistical analysis 
All statistical analysis (Spearman rank correlation, Welch’s t-test, etc.) was 
carried out using the R statistical computing environment (111). 
Results 
Reporter gene assay for loss of function and indole rescue 
To explore the frequency at which a WàG mutation leads to loss of function, we 
developed a reporter gene assay to monitor the loss and rescue of protein 
homodimerization in vivo. As a starting point we used the cI repressor from λ phage, 
which is comprised of an N-terminal DNA-binding domain and a C-terminal 
dimerization domain (112). Upon homodimerization induced by the C-terminal domain, 
the N-terminal domain recognizes a pR promoter to repress downstream gene 
transcription (113). To explore homodimerization in several different proteins, we created 
chimeras by separately fusing each protein to the N-terminal domain of cI. We expressed 
each chimera in E. coli that harbor a GFP gene under control of a pR promoter, and 
monitored GFP fluorescence in these cell cultures. By coupling the target construct 
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dimerization (“function”) to transcriptional repression, this assay provides a 
straightforward readout of the protein’s oligomeric state (Figure 2.1A). 
We applied this assay to test a total of 14 WàG mutations in three separate 
functionally unrelated E.coli genes that encode homodimeric proteins with available 
crystal structures: yeaZ, orn, and tadA (Table 2.1). As controls we used the reporter gene 
plasmid without cI repressor to monitor GFP fluorescence in the absence of repression 
(high RFUs), and we used the wild-type cI repressor to estimate the expected maximal 
repression (low RFUs); neither is strongly indole dependent. Chimeras produced by 
replacing the C-terminal domain of cI with any of the three wild-type homodimeric 
proteins led to repression comparable to that of the intact full-length wild-type cI 
repressor (Figure 2.1B, Table 2.2). 
Upon introducing WàG mutations into these genes, we found that at least half 
disrupted repression of the GFP gene (Figure 2.1B, Table 2.2). The extent of repression 
from these mutants varied broadly: for example, yeaZ W134G and orn W9G had 
fluorescence intensities 96-fold and 59-fold higher than their wild-type counterparts 
(Table 2.2). In contrast, other mutants, such as yeaZ W169G and tadA W34G, 
maintained repressor activity nearly equivalent to that of their wild-type counterparts. 
Subsequent addition of 1 mM indole to the cell cultures appeared to rescue repression in 
a number of cases: for example, yeaZ W123G, yeaZ W134G, yeaZ W159G, and 
orn W9G (Figure 2.1B, Table 2.2). For the mutant showing the greatest indole-induced 
relative difference in repression, yeaZ W123G, we further found that this enhanced 
repression responded smoothly to the concentration of indole (Figure 2.2). Though these 
results suggest that indole may restore dimerization in these mutants, the addition of 
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indole did not result in complete repression of fluorescence back to the wild-type levels, 
most likely because higher concentrations of indole may be required for complete rescue 
(26). Furthermore, despite the unchanged the fluorescence levels of reporter plasmid 
alone and wild-type protein chimeras upon addition of indole (Figure 2.1B, Table 2.2), 
we also cannot fully rule out the possibility that indole may cause the observed decrease 
in fluorescence through some other unrelated mechanism, such as unanticipated 
alterations in E. coli metabolism. 
While this experiment does not explicitly normalize for possible changes in 
expression levels of our chimeric repressors, the observed differences in the behavior of 
WàG single-point mutants within the same construct are unlikely to be attributable to 
altered expression levels. To further investigate how structural changes upon 
incorporation of a WàG mutation may lead to inactivation in this experiment, we turned 











Figure 2.1: Schematic of the cI repressor assay. Various homodimeric proteins (pink) 
are fused to the DNA-binding domain of cI repressor (yellow), enabling binding at the Pr 
promoter and repression of the GFP gene. A WàG mutation that disrupts dimerization 
will lead to loss of repression, and thus increased expression of GFP. If the subsequent 
addition of indole rescues dimerization, repression will be restored and GFP expression 
will decrease. (B) Effect of individual WàG mutations, and the subsequent addition of 
1 mM indole, determined by GFP expression in the cI repressor assay (relative 
fluorescence units, RFU). More than half of the mutations disrupted repression of the 
GFP gene; repression could then be partially rescued by addition of indole in a number of 
cases. Notable examples exhibiting loss of repression and subsequent rescue include 











Table 2.2: Summary of data generated from the cI reporter gene assay and the 
computational analysis of WàG mutations in homodimeric proteins from E. coli. 
# Results from the cI reporter assay. Values are expressed in RFUs (relative fluorescence 
intensity units). The reported uncertainty is the standard error of the mean from 3 
experimental replicates. 
^ Computed from published crystal structures of the wild-type protein. 
@ Results computed from the 100 best-scoring output structures from Rosetta 
refinement. Values are expressed in REUs (Rosetta energy units). The reported 
uncertainty is the standard error of the mean. 
** mutations leading to at least 6-fold loss of repression in the cI reporter assay relative 




















Protein construct GFP 
expression 
in cI assay, 
















None 7389 ± 454 7993 ± 1047 -- -- -- 
Full cI 69 ± 13 86 ± 9 -- -- -- 
yeaZ 78 ± 12 61 ± 26 -- -- -- 
yeaZ W17G 425 ± 311 386 ± 315 17.9 -0.4 ± 8.2 4.8 ± 3.4 
yeaZ W102G 115 ± 6 102 ± 7 31.3 1.5 ± 8.0 3.1 ± 3.3 
yeaZ W123G ** 1689 ± 415 567 ± 143 24.0 1.9 ± 8.3 8.8 ± 3.0 
yeaZ W134G ** 7486 ± 1145 5671 ± 618 28.2 4.6 ± 8.0 15.3 ± 3.4 
yeaZ W159G ** 4678 ± 402 2980 ± 528 36.2 -0.8 ± 8.0 11.8 ± 3.1 
yeaZ W166G 389 ± 138 228 ± 69 27.8 -0.1 ± 7.8 3.7 ± 3.3 
yeaZ W169G 93 ± 5 55 ± 1 28.5 2.4 ± 7.5 8.9 ± 3.1 
orn 74 ± 11 49 ± 8 -- -- -- 
orn W9G ** 4361 ± 305 2089 ± 251 13.9 -0.5 ± 8.1 16.2 ± 3.0 
orn W60G 219 ± 169 134 ± 105 15.8 -0.2 ± 8.0 -2.1 ± 3.1 
orn W95G ** 607 ± 282 696 ± 147 18.3 -0.6 ± 7.9 11.6 ± 3.0 
orn W143G ** 1249 ± 241 684 ± 228 7.2 5.7 ± 8.2 7.3 ± 3.2 
tadA 75 ± 4 99 ± 3 -- -- -- 
tadA W22G ** 493 ± 165 569 ± 86 22.6 -3.0 ± 5.5 11.7 ± 2.3 
tadA W34G 124 ± 32 150 ± 56 17.9 -0.1 ± 5.4 2.3 ± 2.4 






Figure 2.2: Dose-dependent rescue of yeaZ W123G in the cI assay using indole. All 
repression values for a given construct are normalized to the GFP fluorescence for that 








Structural analysis of mutations affecting dimerization 
In order to develop a structure-based approach that would allow us to identify 
which tryptophan sidechains would lead to loss of function when mutated to glycine, we 
first labeled each tryptophan sidechain as “buttressing” (with respect to the dimer 
interface) or “not buttressing.” Sites were labeled as “buttressing” if mutation to glycine 
led to at least 6-fold loss of repression in the cI reporter assay; 7 of the 14 mutation sites 
met this criterion (Table 2.2). We note that each of the proteins included in the cI assay 
has a different fold, and that the mutation sites are dispersed across each protein 
(Figure 2.3A). 
On the basis of our studies of indole rescue in β-glycosidase (26), we expected 
that protein inactivation would again result from an allosteric conformational change that 
coupled disruption at the mutation site to distortion at the functional site (in this case, the 
dimer interface). We further reasoned that such allosteric conformational changes—if not 
explicitly evolved or designed—would be more likely to occur locally than over long 
distances through the protein. As a first indirect test of this hypothesis, we therefore 
computed the distance of each mutation site to the dimer interface, with the expectation 
that the mutations closest to the dimer interface would most frequently be those 
producing loss of repression in the cI assay. 
To evaluate the accuracy of this approach for predicting the effect of these cavity-
forming mutations, we turned to receiver operating characteristic (ROC) analysis. Using 
the distance to the interface as our predictor, we plotted the fraction of true positives 
identified in our set (sites that are “buttressing” and are correctly classified as such) 
versus the fraction of false positives (non-buttressing sites that are incorrectly classified 
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as “buttressing”), for increasing values of the discrimination distance threshold. Using 
this analysis, the curve for a perfect predictor will rise vertically to the upper left corner 
of the plot; in contrast, a method that makes predictions at random have a curve that 
approximately follows the diagonal (red dashed line). While mutations to either of the 
two tryptophan sites closest to the dimer interface indeed led to loss of repression 
(orn W9G and orn W143G), this approach failed to readily identify the other five 
buttressing sites (Figure 2.3B); overall, this predictor performed essentially as a random 
predictor. 
To further explore the hypothesis that disruption at the mutation site could be 
coupled to distortion of the dimer interface through some distinct conformational change, 
we used structure prediction tools in the Rosetta macromolecular modeling suite (77, 114, 
115) to probe the structural consequences of each mutation. We treated prediction of each 
mutant structure as a comparative modeling task, using the crystal structure of the 
wild-type dimer as a template for refinement (see Methods). For each of the resulting 
output structures, we evaluated the interaction energy between the two subunits and 
compared it to the corresponding energy in the wild-type structure: our hypothesis was 
that specific structural changes resulting from mutations at buttressing residues might 
lead to disruption of interactions in the protein-protein interface. However, this approach 
also performed essentially as a random predictor (Figure 2.3C), suggesting that direct 
consideration of interface energetics—predicated on building structural models from the 
wild-type template—was incapable of explaining why certain WàG mutations led to 
loss of repression while others did not. 
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We next surmised that perhaps these drastic cavity-forming mutations had 
destabilized the protein to the point of inducing local or global unfolding (116-119), in 
which case the crystal structure of the wild-type dimer may not prove to be suitable 
template structure prediction. Starting from the premise that the likelihood of a long-
range allosteric conformational change in response to an arbitrary mutation is rare, we 
postulated that a protein could respond in three other ways to a WàG mutation: absorb 
the energetic cost of maintaining a cavity in the hydrophobic core of the protein, undergo 
local collapse of nearby structure to minimize the occupied volume in the core, or unfold. 
Given that the structural response to mutations that decrease sidechain volume can vary 
substantially depending on context (116), we returned to the comparative models we had 
previously built. Using these models, in which local reorganization may have been 
captured by our refinement protocol, we used Rosetta to estimate the stability difference 
of each mutant (dimeric) protein relative to the corresponding wild-type dimer (see 
Materials and Methods). 
In stark contrast to the previous approaches, the estimated stability difference 
proved to be an outstanding predictor of which WàG mutations would lead to loss of 
repression in the cI assay (Figure 2.3D). We further note that the difference in average 
energy associated with each mutant came not from a small number of outlying 
conformations, but rather from a systematic shift in energy over the entire ensemble 
(Figure 2.4); while there is variation from averaging over the set of conformations, the 
nature of these differences thus highlights the robustness of this method for estimating 
stability differences. 
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In addition being a powerful binary classifier, the estimated stability difference 
also gave quantitative correlation with the relative fluorescence measured in the cI 
reporter assay, with Spearman rank correlation coefficient ρ=0.69, a statistically 
significant non-zero value (p < 0.008). The excellent predictive power of this approach 
supports the hypothesis that the loss of dimerization in the cI repressor assay was caused 
by loss of protein stability rather than a discrete conformational change. To test this novel 


















Figure 2.3: Structural analysis of mutations affecting dimerization. (A) Distribution 
of WàG mutation sites over the three homodimeric proteins used in the cI assay. 
Mutation sites that led to loss of repression are shown in magenta, the other mutation 
sites are shown in yellow. The dimer subunits are colored green and blue, respectively. 
(B) A receiver operating characteristic (ROC) plot for predicting whether a given 
mutation will lead to loss of repression in the cI assay, using the distance from the 
mutation site to the dimer interface as the predictor. The area under the curve is 0.51, 
indicating that this method performs about as well as making predictions purely at 
random (the red dashed line in each ROC plot corresponds to a random predictor). (C) 
An analogous ROC plot generated by using the difference in interface energy of 
comparative models to predict whether a given mutation will lead to loss of repression in 
the cI assay. The area under the curve is 0.41, indicating that this method is not predictive 
of the data. (D) An analogous ROC plot generated by using the estimated stability 
difference from the same set of comparative models. The area under the curve is 0.94, 
indicating that this method performs much better than a random predictor; the difference 
from a random predictor is statistically significant (p < 0.004). The identification of 
stability difference as a successful predictor for loss of function suggests that, at least in 
















Figure 2.4: Energy distribution for each protein construct in the cI reporter assay, of the 
100 top-scoring output structures from Rosetta refinement simulations. The mean energy 
is shown as a horizontal bar across the box, while the height of the box indicates two 
times the standard error of the mean. Boxes filled in red denote mutations that led to at 
least 6-fold loss of repression in the cI reporter assay relative to the corresponding 
wild-type construct. Boxes filled in green denote mutations that did not lead to at least 
6-fold repression. 
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Mechanism of inactivation and rescue in +5 GFP 
Due to the inherent challenges associated with the biochemical and structural 
characterization of homodimers, we elected to explore whether the same stability-
mediated mechanism of inactivation and rescue occurred in a model system more 
naturally amenable to these in vitro techniques. We selected +5 GFP for these studies, a 
variant of “superfolder” GFP (88). Like most GFP constructs, +5 GFP folds into a 
β-barrel harboring a single tryptophan residue (Trp57) on the central helix, 10 Å from the 
chromophore (88). Simulations analogous to those described above gave an estimated 
stability difference of 4.5 Rosetta energy units associated with this W57G mutation; this 
value nearly, but not quite, reaches the threshold of 5.0 over which we regularly observed 
loss of function in the cI reporter assay (Table 2.2). 
We measured the fluorescence intensity of wild-type +5 GFP and its W57G 
mutant, and found that deletion of this tryptophan sidechain reduced the fluorescence 
intensity by 50% (Figure 2.5A). While addition of 1 mM indole led to a slight decrease 
in fluorescence intensity for the wild-type protein, indole instead rescued fluorescence in 
the W57G mutant, back to 63% of the wild-type value (the difference in fluorescence 
intensity upon addition of indole to +5 GFP W57G is statistically significant, p < 0.001 
using Welch’s t-test). Rescue of W57G fluorescence by indole increases in a 
dose-dependent manner (Figure 2.6). 
It is well established that slight structural rearrangements close to the GFP 
chromophore can lead to dramatic spectral differences (120, 121); the fluorescence 
properties can thus serve as a sensitive readout of the local environment surrounding the 
chromophore. We therefore carried out excitation and emission wavelength scans for 
 47 
both GFP constructs (Figure 2.5B). The shapes of the wild-type and W57G spectra are 
identical, notwithstanding a 46% decrease in intensity upon mutation (consistent with 
Figure 2.5A). The addition of 1 mM indole did not change either curve shape, save the 
same intensity differences observed previously (Figure 2.5A). Collectively, the lack of 
peak shifts or additional peaks in these spectra suggests that the partial inactivation and 
rescue we observed was not coupled to reorganization of the packing around the 
chromophore. 
Based on the unchanged excitation and emission maxima, we formulated the 
hypothesis that in the absence of indole, +5 GFP W57G populates two states. The first, 
comprised of 46–50% of the population, is characterized by a conformation very similar 
to that of wild-type +5 GFP and accounts for the native-like excitation and emission 
spectra. The second state, accounting for the remaining 50–54% of the population, may 
be partly unfolded or have changes in conformational dynamics that disrupt the 










Figure 2.5: Mechanism of inactivation and rescue in +5 GFP. (A) 
Fluorescence intensity of +5 GFP constructs, with excitation at 485 nm and emission at 
528 nm. The indole concentration was 1 mM. Error bars indicate the standard error of the 
mean from 10 replicate measurements. *** statistically significant difference at p < 
0.001. (B) Excitation and emission spectra of +5 GFP constructs. The indole 
concentration was 1 mM. (C) Crystal structure of W57G +5 GFP refined to 1.6 Å 
resolution (green and magenta), superposed with wild-type superfolder GFP (gray and 
blue). (D) Coomassie-stained SDS-PAGE gel showing products of pulse proteolysis 
reactions. Incubation with subtilisin led to more extensive degradation of W57G +5 GFP 



























Figure 2.6: Dose-dependent rescue of +5 GFP W57G fluorescence using indole. Original 
fluorescence measurements indicated that +5 GFP W57G fluorescence was 50% that of 
WT, and reached 63% that of WT upon addition of 1 mM indole (Figure 2.5A,B). The 
data shown here were collected using samples of both W57G and WT produced 
separately. While these samples reach 63%, W57G has 59% the fluorescence of the WT 
prior to addition of indole. We cannot explain the origin of this difference, but speculate 









To test this hypothesis, we solved the crystal structure of +5 GFP W57G to 1.6 Å 
resolution (Table 2-3). While it was somewhat surprising to obtain crystals from the 
heterogeneous population we anticipated, we postulate that the (non-equilibrium) process 
of crystallization allowed us to capture the native-like (fluorescent) state. Accordingly, 
our solved structure of +5 GFP W57G closely resembles the structure of wild-type 
+5 GFP previously determined (88), with overall Cα RMSD of 0.84 Å (229 residues), Cα 
RMSD for residues within 4 Å of the chromophore of 0.25 Å (21 residues), and no 
structural differences evident in response to the mutation (Figure 2.5C). We also found 
that +5 GFP W57A exhibited similar fluorescence properties as +5 GFP W57G including 
rescue by indole (Figures 2.7, 2.8), and yielded crystals that diffracted to 1.1 Å 
resolution. Like +5 GFP W57G, the crystal structure of +5 GFP W57A showed no 
structural differences relative to the wild-type structure, including the backbone at the site 
of the mutation (Figures 2.9, 2.10). Interestingly, the +5 GFP W57A structure revealed a 
water molecule located exactly at the position previously occupied by the indole nitrogen 
of Trp57, recapitulating the hydrogen bond to a nearby aspartate observed in the 
wild-type structure (Figure 2.11). While both the W57G and the W57A structures 
contain a large cavity previously filled by the tryptophan sidechain, this cavity is neither 
completely occluded from solvent nor completely hydrophobic; this makes it 





Figure 2.7: Fluorescence intensity of +5 GFP constructs, with excitation at 485 nm and 
emission at 528 nm. The indole concentration was 1 mM. Error bars indicate the standard 
error of the mean from 10 replicate measurements. The same data for WT and W57G are 













Figure 2.8: Excitation and emission spectra of +5 GFP constructs. The indole 







Figure 2.9: Fo-Fc omit maps contoured at 3σ showing residue 57 of +5 GFP W57G (left) 



















Figure 2.10: Left: Comparison of +5 GFP W57G and +5 GFP W57A. The overall Cα 
RMSD is 0.32 Å (over 225 residues). Right: Comparison of WT superfolder GFP, 
+5 GFP W57G, and +5 GFP W57A showing the similarity around residue 57 amongst all 
three structures. In both panels the chromophore is colored grey, WT superfolder GFP is 
colored green, +5 GFP W57G is colored magenta, and +5 GFP W57A is colored cyan. 












Figure 2.11: Left: WT superfolder GFP (PDB ID 2B3P), showing the hydrogen bond 
from Trp57 to Asp216. Right: +5 GFP W57A showing the analogous region. A water 
molecule (red sphere) adopts the position previously occupied by the indole nitrogen of 
Trp57, and forms a hydrogen bond with Asp216 and the backbone carbonyl of His217. 
















With this evidence that fluorescence in +5 GFP W57G derives from a species 
having essentially the wild-type structure, we next sought evidence for an alternate state 
comprising the remainder of the population. To probe for such a state we carried out a 
pulse proteolysis experiment, incubating either of wild-type +5 GFP or its W57G mutant 
with subtilisin. We found that while the folded native structure of wild-type +5 GFP 
renders it largely protected from proteolysis, the W57G mutant is extensively digested 
almost immediately (Figure 2.5D). We further found that inclusion of a protease 
inhibitor (PMSF) in the reaction prevents loss of +5 GFP W57G, while DMSO (used as a 
vehicle for PMSF) does not (Figure 2.12). The fact that PMSF prevents the 
disappearance of W57G +5 GFP serves to confirm that indeed proteolysis is responsible, 
and not some other process such as aggregation. The susceptibility of +5 GFP W57G to 
proteolysis supports the hypothesis that in addition to a state that strongly resembles 
wild-type +5 GFP, this mutant also populates a state in which subtilisin cleavage sites are 
more exposed than in its native-like (fluorescent) conformation. While we speculate that 
addition of indole would confer enhanced subtilisin resistance to W57G +5 GFP, we 
found through separate control experiments (not shown) that indole itself inhibits this 







Figure 2.12:  (A) An uncropped image of the Coomassie-stained SDS-PAGE gel 
showing products of proteolysis reactions from the +5 GFP constructs. (B) An uncropped 
image of a Coomassie-stained SDS-PAGE gel showing addition of the protease inhibitor 




Collectively, these observations point to a model in which incorporation of the 
W57G mutation into +5 GFP induces unfolding or enhanced fluctuations in a subset of 
the population (loss of fluorescence intensity), followed by a shift in this population back 
to the native-like state upon addition of indole (rescue of fluorescence intensity). This 
model is qualitatively distinct from the mechanism of inactivation and rescue we 
observed in our characterization of β-gly W33G (26). 
Mechanism of inactivation and rescue in β-glucuronidase 
Motivated by this stability-mediated model for inactivation and rescue of +5 GFP 
W57G, we returned to the E. coli β-glucuronidase (β-gluc) W492G mutant described 
previously (26). We had characterized this enzyme only in passing as part of our initial 
studies of indole rescue, showing that indole could be used to partially restore activity to 
this mutant in a dose-dependent manner. Though the structure of the wild-type enzyme 
has been solved via X-ray crystallography (122), we found that the W492G mutant was 
not amenable to crystallization. We further applied the Rosetta refinement tools (77, 115) 
to build comparative models of the W492G mutant, with the structure of the wild-type 
enzyme as a template; none of these models, however, included a conformational change 
linking the mutation site to the active site. In the absence of any structural insights we 
were, at the time, unable to explain the basis for the loss of enzyme activity due to this 
mutation (26), particularly given that the mutation site lies 13 Å from the enzyme active 
site. 
In light of the studies we reported above, we formulated the hypothesis that the 
indole-dependent activity of β-gluc W492G may also be modulated by enhanced 
fluctuations or local/global unfolding, which are then reverted upon addition of indole. 
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This hypothesis could explain our inability to form crystals of the W492G mutant, and 
also our inability to build a compelling model of the structure of this protein. This 
hypothesis was further supported by the stability difference of 6.5 Rosetta energy units 
estimated for this W57G mutation, above the threshold of 5.0 that proved predictive in 
the cI reporter assay (Table 2.2). 
To directly test this hypothesis, we used hydrogen/deuterium (H/D) exchange 
experiments to probe local fluctuation events in the protein. Upon incubation with 
deuterium-containing solvent, amides that are not strongly hydrogen bonded are more 
rapidly isotopically labeled than amides involved in intramolecular hydrogen bonds (123-
126). Consequently, hydrogen–deuterium exchange allows us to localize conformational 
differences between β-gluc variants or upon addition of indole. The large size of this 
enzyme precluded straightforward residue-level localization of deuterium exchange 
information via NMR. For this reason, we instead quenched the exchange reaction, used 
pepsin to digest the protein, and then quantified the extent of exchange for each peptide 
fragment via mass spectrometry (127). A total of 147 peptides, of average length 13 
residues, collectively covered 82% of the whole protein sequence excluding proline 
residues (Figure 2.13); this included good coverage near the active site and the mutation 
site (Figure 2.14A), and extensive overlap in many regions. We separately incubated 
wild-type β-gluc and the W492G variant in deuterium-containing buffer, both in the 
absence of indole and in the presence of 5 mM indole. Aliquots at multiple time points 
were digested and analyzed by mass spectrometry to determine the degree to which the 
protein environment conferred protection from exchange at specific regions of the protein 
(Figure 2.15). 
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Relative to the wild-type enzyme, a number of segments from the W492G variant 
showed enhanced deuterium uptake, corresponding to less protection by the protein 
environment. Upon addition of indole, many of the same peptides exhibited decreased 
deuterium uptake, suggesting that indole reverted the effect of this mutation (Figure 
2.16). To allow direct comparison between peptides of different sizes, we calculated for 
each peptide the “normalized deuterium difference”, NDD, defined as the difference in 
peptide mass increase per exchangeable amide hydrogen, averaged over all time points 
(see Materials and Methods). To further localize the effect of mutation and indole rescue, 
we then returned to the mapping of each peptide to the protein sequence. At every 
position in the protein sequence, we assigned the normalized deuterium difference for the 
residue as the average NDD value for all peptides covering its position in the sequence. 
While this does allow calculation of an NDD value for all residues covered by at least one 
peptide, we note that these NDD values are not truly residue-resolved, since each peptide 
represents information integrated from adjacent residues as well as the residue of interest. 
Relative to the wild-type enzyme, we observe enhanced deuterium uptake in the W492G 
mutant that is localized to specific regions of the protein sequence (Figure 2.14B). 
Addition of indole to the wild-type enzyme does not result in appreciable changes in 
deuterium uptake (Figure 2.14C); in contrast, addition of indole to β-gluc W492G leads 
to protection against deuterium uptake (Figure 2.14D). We further note that most of the 
regions in this mutant that exhibit increased protection upon addition of indole are the 
same as those that showed enhanced deuterium uptake as a result of the mutation. Upon 
comparing deuterium uptake between wild-type β-gluc and W492G with 5 mM indole 
present in both, we find that indole does not change the pattern but slightly reduces the 
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magnitude of the differences (Figure 2.17). Our observation that the enhanced deuterium 
uptake of the mutant is not fully abrogated by addition of 5 mM indole is not surprising, 
given that we previously observed only partial rescue of enzyme activity at this indole 
concentration (26). 
Mapping NDD values to the structure of the wild-type enzyme reveals a cohesive 
picture of inactivation and rescue. First, introduction of the W492G mutation leads to less 
protection from deuterium uptake in a nearby region that includes two helices and several 
intervening loops, indicating that loss of function in response to this cavity-forming 
mutation occurs due to enhanced fluctuations or local unfolding (Figure 2.14E). 
Addition of indole then restores protection from deuterium uptake at the same regions 
(Figure 2.14F), suggesting rigidification or refolding of these regions around the indole. 
These changes induced by addition of indole (partially) shift the conformational 
ensemble back towards that of the wild-type enzyme, thus providing a structural 










Figure 2.13: Unambiguously assigned peptic peptides of β-glucuronidase span most of 
the protein. Residues with an exchangeable backbone amide hydrogen that were not 
covered by at least one peptide are colored red; the remaining residues are colored 
yellow. Excluding proline residues (which lack an exchangeable backbone amide 
hydrogen), coverage comprises 82% of the protein sequence. The location of Trp492 is 










Figure 2.14: Mechanism of inactivation and rescue in β-glucuronidase as revealed 
by hydrogen–deuterium exchange analysis. (A) Peptic peptides provide thorough 
coverage of the β-gluc active site. Residues with an exchangeable backbone amide 
hydrogen that were not covered by at least one peptide are indicated in red; the remainder 
of the protein is shown in yellow. The locations of Trp492 (orange) and a substrate 
analog (blue) are shown in spheres. (B) Comparison of deuterium uptake (“normalized 
deuterium difference”, NDD) between wild-type β-gluc and W492G; positive values 
indicate enhanced deuterium uptake in the mutant. (C) Effect of adding 5 mM indole to 
wild-type β-gluc. (D) Effect of adding 5 mM indole to β-gluc W492G; negative values 
indicate increased protection from deuterium uptake upon addition of indole. 
(E) Mapping the mutant versus wild-type NDD to the β-gluc protein structure reveals a 
spatial localization of residues that undergo enhanced deuterium uptake in β-gluc W492G 
relative to the wild-type. The color of each residue reflects the normalized deuterium 
difference between the mutant and wild-type, using a gradient from purple (most 
enhanced deuterium uptake in the mutant, relative to the wild-type) to green (most 
protected in the mutant, relative to the wild-type). (F) Mapping the absence versus 
presence of indole NDD to the β-gluc protein structure reveals the pattern of changes that 
occur upon addition of indole. Each residue is colored using a gradient from purple (most 
enhanced deuterium uptake upon addition of indole) to green (most protected upon 












Figure 2.15: Deuterium uptake curves for four representative peptides of 
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Figure 2.16: Hydrogen–deuterium exchange analysis of β-glucuronidase. The W492G 
mutation to β-gluc leads to enhanced deuterium uptake for many peptides relative to the 
corresponding peptides from the wild-type enzyme (red). Addition of indole to β-gluc 
W492G leads to decreased deuterium uptake for many of the same peptides (blue). The 
magnitude of deuteration differences is reported as the sum of the differences over all 
time points, ΣΔΔm. Peptides are listed in order of their sequence midpoint relative to the 




































Figure 2.17: A comparison of deuterium uptake (“normalized deuterium difference”, 
NDD) between wild-type β-gluc and W492G, with 5 mM indole present in both. Positive 
values indicate enhanced deuterium uptake in the mutant. The pattern of protected 
residues is similar to the analogous comparison carried out in the absence of indole 











In our earlier work (26) we identified two examples of residues required for 
buttressing the nearby active site: removal (via cavity-forming mutation) of a sidechain 
playing this key role in maintaining the protein architecture results in collapse of the 
active site geometry, and thus loss of function. Our structural studies of β-gly W33G 
revealed a distinct conformational change induced by the cavity-forming mutation, which 
fortuitously transduced this disruption to the active site. Predicting the long-range effects 
of structural variations in general represents a very challenging problem (128-132), 
making it exceedingly unlikely that such predictions can be routinely used to introduce 
analogous mutations for building allosteric control into other proteins. 
The systematic evaluation of a larger test set in our cI repressor assay (Figure 2.1) and 
the subsequent computational analysis (Figure 2.3), implied that protein structure and 
function could instead be modulated indirectly, through control of protein stability. In 
both examples for which we subsequently carried out detailed biochemical studies 
(Figure 2.5, 2.14), we found strong evidence pointing to enhanced fluctuations or 
unfolding resulting from destabilization as the mechanism underlying loss of function 
upon mutation. Accordingly, reactivation by indole may occur not only by reversion of a 
discrete conformational change (as in β-gly W33G), but alternatively by rigidifying or 
refolding the protein to its active state. 
It is also noteworthy that all of the proteins characterized here derive from 
mesophilic organisms, whereas the β-glycosidase we studied previously derives from a 
hyperthermophilic organism (Sulfolobus solfataricus). The extreme stability of β-gly may 
have rendered it resistant to unfolding, allowing it to instead respond to the cavity-
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forming mutation via the conformational change we described earlier (26). In light of the 
results presented here, we expect that modulation of function via chemical rescue of 
structure will rely, for most proteins from mesophilic organisms, on stability-mediated 
mechanisms. 
In order to build small-molecule dependence into a protein domain via chemical 
rescue of structure, the cavity-forming mutation must induce the protein to undergo a 
transition to some non-functional state (Figure 2.18); however, the precise details of this 
inactive state need not be explicitly designed. Attempting to rationally identify cavity-
forming mutations to inactivate some protein of interest via a discrete conformational 
change would prove exceedingly challenging; on the other hand, evaluating the stability 
difference associated with cavity-forming mutations represents a far more tractable task. 
Accordingly, we expect that the insights offered here will immediately enable rational 
design of a variety of new protein switches that rely on activation by indole-induced 
protein stabilization. 
Natural systems make use of small-molecules to encode a broad range of signals, 
whose diversity is reflected in the wide variety of mechanisms that are used to transduce 
ligand binding into downstream activity (97). These mechanisms range from discrete 
conformational changes (133, 134), to population shifts (135-137), to induced folding 
(138-141). There are specific design advantages associated with using each distinct 
mechanism: these may include intrinsic differences in dynamic range (142), selectivity 
(143, 144), kinetics (141, 145), and the ability to modulate signals by altering cellular 
accumulation through resistance to proteolysis (140, 146). Using chemical rescue of 
structure, we have already observed a similar range of mechanisms for recognition and 
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activation in our set of designed protein switches. This leads to the prospect of “designing 
in” the desired signaling mechanism, by carefully selecting a protein of appropriate 
structure and stability. By analogy to natural systems, this in turn may allow us to tune 
the specific properties of de novo switches and sensors built through chemical rescue of 
structure, to optimally cater the designed system to the unique criteria associated with any 
new application.
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Figure 2.18: United model of inactivation and rescue. A protein may respond to a 
cavity-forming WàG mutation by undergoing a discrete conformational change, as seen 
in our previous study (26), or through stability-mediated mechanisms, as described here. 








Chapter III.  
Generalizing Chemical Rescue of Structure to Neighboring Amino Acids 
Abstract 
The ability of engineering switch-like regulation of protein function by small-
molecule signal is a long-standing goal in basic biological research and biotechnology. 
Our laboratory has recently developed an approach, termed “chemical rescue of 
structure”, which enables the modulation of protein function by disrupting and restoring 
protein structure. The existing designs of protein switches through this approach require a 
single tryptophan-to-glycine mutation, and the subsequent rescue by indole. However, 
these requirements restrain the selection of applicable protein scaffolds, and result in 
relatively insensitive protein switches due to the limited binding affinity provided by 
indole. 
I wished to test whether the chemical rescue of structure approach might be 
generalized to utilize multiple neighboring mutations, such that small molecules 
mimicking the three-dimensional geometry of the removed moieties could be used to 
restore the protein structure. This generalization would resolve the limitation from indole-
based systems, extending the applicability of chemical rescue of structure to more protein 
scaffolds. In addition, matching to multiple removed sidechains should enable the 
identification of more diverse and hydrophobic small molecules, which may increase the 
binding affinity and membrane permeability when used in cell-based assays. As a first 
test of the generalized chemical rescue of structure, I applied it to ChxR, a homodimeric 
two-component response regulator in Chlamydia trachomatis. Using the deleted chemical 
groups as a template for ligand-based screening, I successfully identified small molecules 
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that exhibited specific binding to the engineered ChxR variant. These preliminary results 
support the feasibility of generalized chemical rescue of structure approach, and can 
potentially enable the design of diverse protein switches and sensor proteins targeting 
various small molecules, especially the ones that lack the natural binding proteins. 
Introduction 
The switch-like modulation of protein function via small-molecule signals is a 
common theme in natural-occurring signaling systems. The engineering of these systems 
has also helped elucidate the mechanism of key processes. We recently described an 
approach for engineering such switch-like control into proteins via a strategy termed 
“chemical rescue of structure” (26, 27). This strategy entails introducing one or more 
cavity-forming mutation at locations critical for the local or global structural integrity. 
Deletion of these critical sidechains induces the protein to undergo diverse structural 
changes, and lead to loss of protein function. The subsequent addition of exogenous 
compounds that resemble the deleted moieties is then expected to complement the deleted 
structural elements, and thus restore protein structure and function. 
Previous protein switches designed through chemical rescue of structure solely 
rely on using a single tryptophan to glycine (WàG) mutation to inactivate the enzymatic 
activity. Exogenous indole, which perfectly complements the deleted sidechain, restores 
the original protein conformation, and thus rescues the function. However, there are 
intrinsic limitations to the indole rescue paradigm: its application is restricted to protein 
scaffolds in which a single WàG mutation leads to loss-of-function. The selection of 
rescuing compounds is also confined to indole and its simple derivatives, whose small 
size and hydrophobic surface limit the binding affinity. In addition, the metabolic indole 
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existing endogenously in cells may cause leaky activation of the engineered protein 
switches in vivo. 
In principle, however, the chemical rescue of structure approach can be 
generalized to use multiple amino acids, rather than a single tryptophan. In this case, the 
removal of a constellation of atoms from neighboring sidechains creates a larger buried 
cavity and induces the loss of protein function. In the following rescuing stage, small 
molecules resembling the structural geometry and chemical property of the removed 
chemical groups can be identified through ligand-based screening and used to 
complement the cavity and restore the protein structure and function.  
This generalization vastly increases the versatility of chemical rescue of structure 
in designing protein switches: it extends the application to target principally all protein 
hosts, including the ones lacking buried tryptophan residues. By selecting different 
combinations of neighboring amino acids as templates, the chemical space of candidate 
compounds is enlarged and contains more diverse chemical scaffolds. The matching to 
multiple removed sidechains also increases the size and hydrophobicity of candidate 
small molecules, which may provide more favorable binding affinity and better 
membrane permeability in cell-based assays. Furthermore, “bio-orthogonal” small 
molecules (those distinct from endogenous metabolites) may reduce the potential for 
inadvertent activation in indole-based systems. Furthermore, the generalized chemical 
rescue of structure approach can also be used in a converse direction to enable the 
construction of sensor proteins. In this case, we can select mutations to match the three-
dimensional structure of a given small molecule, rather than selecting small molecules to 
complement the cavity space.  
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In this study, I applied this approach to a model protein and identified small 
molecules that can specifically bind to the engineered protein host. This study establishes 
the feasibility of a generalized chemical rescue of structure approach, and I anticipate that 
these findings will help the construction of novel protein switches and sensor proteins 
through the proposed approach. 
Materials and Methods 
Plasmid, site-direct mutagenesis, and protein expression 
A pET28b plasmid containing the full length Chlamydia trachomatis ChxR gene 
was generously provided by Dr. Scott Hefty (University of Kansas). Point mutations were 
introduced using the QuikChange methodology (Stratagene). Primers used to introduce 
the F75A, W89G and F75A/W89G mutations were designed by the QuickChange Primer 
Design server (http://www.genomics.agilent.com/primerDesignProgram.jsp). 
Recombinant wild-type and mutant ChxR were expressed from the pET28b vector 
in E. coli Rosetta 2(DE3)pLysS cells at 15ºC overnight. The cells were resuspended in 
Lysis Buffer (50 mM Tris, 150 mM NaCl, 5 mM imidazole pH 8.0) and sonicated for 10 
minutes (Fisher Scientific Sonic Dismembrator Model 100). The cell lysates were then 
centrifuged at 15,000g for 30 min. Wild-type and mutant ChxR remained in the 
supernatant, which was purified by HPLC affinity chromatography with Ni-chelated 
Sepharose Fast Flow Resin (GE Healthcare), followed by a HiLoad 16/60 Superdex 75 
gel filtration column (GE Healthcare). All protein concentrations were determined with 
reference to bovine albumin standards using Bradford assays. 
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ROCS screening 
I used ROCS to screen large libraries for compounds that match the template. I 
downloaded the standard ‘drugs-now’ subset of ~7 million molecules from ZINC 
database for screening. I generated up to 100 conformers for each molecule in the 
database using OMEGA. I screened the database using the hotspot pharmacophore (using 
default ROCS parameters), and carried forward the top 500 compounds ranked by 
'TanimotoCombo' score. I then aligned these back to the protein using the hotspot 
pharmacophore, then carried out a gradient-based full atom minimization of the complex 
using the Rosetta energy function. The top-scoring compounds were visually inspected 
and selected for experimental validation based on cost and availability. 
Surface Plasmon Resonance 
 Binding between W89G ChxR and each compound were analyzed by SPR using a 
Biacore 3000 optical biosensor (GE Healthcare). His-tagged ChxR was immobilized by 
Ni2+/NTA chelation on a NTA sensor chip (GE Healthcare). An unmodified flow cell was 
used as reference. Wild-type ChxR was also immobilized on another flow cell as a 
negative control. All SPR runs were performed at 25 ºC using a flow rate of 50 µL/min in 
running buffer (HEPES buffered saline with 0.05% Tween-20 pH 7.4). Compounds were 
injected over sample and reference flow cells at a concentration of 100 µM in running 
buffer for 100 s, followed by a dissociation phase for 200 s. Sensorgram data were 
processed using BIAEvaluation (GE Healthcare Life Sciences) and the figures were 
prepared by Prism (GraphPad, La Jolla, CA). 
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EMSA 
IR800-labeled Oligonucleotides containing ChxR binding sites DR2 were was 
generously provided by Dr. Scott Hefty (University of Kansas). Binding reactions (20 µl) 
contained DNA and ChxR at their respective concentrations, as listed in Results and were 
performed. The reactions were incubated at 25°C for 20 min and separated by 
electrophoresis in 5% TBE gel, 0.5× TBE buffer at 50 V for 2 h.. After native PAGE, 
IR800-labeled DNA fragments were visualized by using the Odyssey Infrared Imaging 
System (LI-COR Biosciences, Lincoln, NE). 
Results 
ChxR: a model protein for testing the generalized chemical rescue of structure 
We selected a dimeric protein, ChxR, to test the feasibility of applying chemical 
rescue of structure with multiple neighboring mutations. ChxR is a signal transduction 
response regulator of the OmpR/PhoB subfamily encoded by Chlamydia trachomatis 
(147). ChxR is composed of a receiver domain and an effector domain: the receiver 
domain drives the homodimerization of two monomeric subunits, and consequently 
positions the effector domain to the structural arrangement optimal for DNA binding 
(148, 149). This homodimerization is an essential structural feature that determines the 
correct functioning of ChxR: disruption of ChxR dimeric interface greatly reduces the 
binding affinity to the target DNA sequences (147). Visual inspection of the 
homodimeric interface of the receiver domain reveals the structural importance of a pair 
of neighboring tryptophans on opposing sides of the interface (W89 on chain A and W89 
on chain B), which correspond to the same residue in the primary structure of a ChxR 
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subunit (Figure 3.1A). These symmetry-related tryptophan residues are in direct contact 
and compactly buried in the critical position of the dimeric interface.  
The critical location of the pair of tryptophan residues in the dimeric interface and 
the direct coupling of structural dimerization and DNA binding activity make ChxR an 
ideal model protein for testing the generalized chemical rescue of structure approach. A 
single W89G mutation on the monomeric subunit leads to the removal of two 
neighboring tryptophan sidechains in the native dimeric structure. These cavity-forming 
mutations, in combination with other background mutations if necessary, can perturb the 
dimeric interface and induce ChxR to undergo a transition to some nonfunctional 
conformation. Subsequently, we can identify small molecules complementing the deleted 
structural elements and investigate their ability of restoring native dimeric structure, and 













Figure 3.1: Generalized chemical rescue of structure using ChxR. (A) Crystal 
structure of ChxR receive domain (PDB: 3Q7R) showing the symmetry-related pair of 
tryptophan residues (W89) at the dimeric interface (spheres representation). Monomeric 
subunits are colored in green and cyan, respectively.  (B) Small molecules (yellow sticks) 
that can potentially mimic the three-dimensional structure and chemical property of the 













Identification and biochemical characterization of computational hits 
The first step is to identify small molecules that recapitulate the precise three-
dimensional structure of the deleted structural elements. For this purpose, I used the 
geometric arrangement of the pair of indole moieties in the native ChxR structure as a 
template for carrying out ligand-based virtual screening. To facilitate rapid 
characterization of compounds emerging from the virtual screen, I restricted the search to 
around seven million compounds in the ZINC database (150) that are both commercially 
available and predicted to have drug-like physicochemical properties. I used OMEGA 
(OpenEye Scientific Software, Santa Fe, NM) to build low-energy conformations of each 
compound, then ROCS (OpenEye Scientific Software, Santa Fe, NM) to align each 
conformation to the pair of indole moieties and quantitatively measure the three-
dimensional similarity between the template and small molecule. For each of the top-
scoring hits emerging from ROCS, I then used the aligned orientation to position the 
compound relative to the protein, and evaluated the potential binding models. 
Through the virtual screening, I identified nine hit compounds (Figure 3.2). 
These compounds consist of different ring systems, connected by various linker 
fragments. However, they can potentially adopt conformations that resemble the three-
dimensional geometry of the removed pair of indole moieties (Figure 3.2A). Because of 
this structural similarity, superposition of these hit compounds back to the removed 
tryptophan sidechains at the ChxR dimeric interface demonstrates that these compounds 
can potentially recapitulate the hydrophobic packing and, in certain examples, hydrogen 
bonding interaction, from the deleted tryptophan sidechains (Figure 3.2B). 
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Figure 3.2: The nine computational hit compounds. (A) The three-dimensional model 
of hit compounds (C1 – C9, assorted colors) superposed with the template (W89 
sidechains, colored in green and cyan). (B) Potential binding models of each hit 
compound built from positioning the aligned structures of hit compounds back to the 
ChxR dimeric interface. Monomeric subunits of ChxR are colored in green and cyan, 
























As the first test, I directly examined the binding of each candidate compound to 
W89G ChxR mutant using surface plasmon resonance (SPR) (Figure 3.3). The ChxR 
variant was immobilized onto an SPR chip and then I sequentially passed each compound 
over the chip at a concentration of 100 µM. All of the nine top-scoring compounds 
showed a kinetic profile consistent with binding to the W89G ChxR. In contrast, except 
for the slight increase of signal for C9, none of the other eight compounds bind to the 
wild-type ChxR, suggesting that the binding of hit compounds is a direct consequence of 
W89G mutation (Figure 3.3A). However, considering the hydrophobicity of the hit 
compounds, another possibility is that these compounds may promiscuously bind to the 
exposed hydrophobic surface caused by local or global unfolding in the W89G mutant. 
Therefore, I also included an unrelated compound of similar size and hydrophobicity as a 
further negative control, This compound does not show any evidence of binding to either 
protein construct, suggesting that the positive signal from SPR is not a result of non-
specific binding to the “sticky” hydrophobic surface of the ChxR mutant, but rather 
specific binding arising from the three-dimensional complementarity of the small 









Figure 3.3: Initial screening via surface plasmon resonance. (A) SPR sensorgrams 
testing the binding of each hit compound to either W89G (red traces) and wild-type (blue 
traces) ChxR. (B) SPR sensorgrams of unrelated compound (blue trace) serving as a 
negative control. Sensorgram of C1 (red trace) is included as an example of kinetic 















































































































Designing suitable ChxR variant for testing functional rescue 
The specific binding of hit compounds to W89G ChxR led me to further 
investigate whether this binding could lead to structural restoration and functional rescue. 
A prerequisite, however, is to examine if the W89G ChxR mutant is a loss-of-function 
variant. To this end, I employed an electrophoretic mobility shift assay (EMSA) to 
directly detect the protein:DNA complex between the W89G variant and DR2 sequence, 
a DNA fragment recognized by ChxR with high affinity (147). Unfortunately, the DR2-
binding profile exhibited by the W89G variant is indistinguishable from the wild-type 
counterpart, showing that the W89G mutation alone is insufficient to cause the loss of 
DNA-binding activity (Figure 3.4A). 
This finding prompted me to construct a ChxR variant harboring an auxiliary 
background mutation that is distal from the pair of tryptophans at the dimeric interface. 
This mutation, when made alone, should still possess the wild-type level of DNA-binding 
activity, but cause a significant loss of binding affinity in combination with W89G. Such 
ChxR variant can serves as a “pseudo wild-type” platform to incorporate the W89G 
mutation and test the subsequent rescue by complementing small molecules. Taking heed 
of these requirements, further examination of the dimeric interface suggests F75A to be 
an excellent choice as the auxiliary mutation (Figure 3.4B). The F75 residue interacts 
with P94 from the opposing subunit, and is located remotely from W89 with a shortest 
distance of 11 Å. Therefore, the removal of the F75 sidechain will cause a disconnected 
void volume from the W89G cavity, and most likely have no influence to the engineered 
small-molecule binding location. In addition, the peripheral position of F75 at the dimeric 
interface suggests that this FàA mutation conveys less energetic penalty to the stability 
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of the ChxR dimer comparing to W89G. These observations lead to the hypothesis that 
the F75A mutation alone is insufficient to cause detectable loss of DNA-binding activity. 
However, the W89G mutation in combination with this background mutation will lead to 
a significant loss of function. As expected, the F75A mutant still forms the protein:DNA 
complex, with levels similar to the wild-type and the W89G variant. The W89G to this 
pseudo wild-type construct, however, completely lost the DNA-binding activity (Figure 
3.4A). These observations suggest that the F75A ChxR variant can be used as a pseudo 
wild-type construct to incorporate the W89G mutation and examine the subsequent 
















Figure 3.4: Construction of pseudo wild-type ChxR variant. (A) W89G ChxR variant 
still demonstrates DNA binding activity identical to that of the wild type. F75A mutation 
alone does not lead to loss-of-function. Combining the two mutations, however, the 
F75A/W89G ChxR variant shows complete abolishment of DNA-binding activity. (B) 
Left panel: The position of F75 is distant from W89. W89 residues are shown in spheres; 
F75 residues are shown in magenta sticks. Right panel: P94 (green and cyan spheres) 
























Discussion and Future Steps 
In this study, I evaluated the generalized chemical rescue of structure approach 
using ChxR as a model structure, and identified small molecules that can specifically 
bind to the engineered ChxR mutant. The immediate next step is to characterize whether 
the binding of hit compounds identified by SPR can rescue the DNA binding activity of 
F75A/W89G ChxR. Biochemical assays, such as EMSA and fluorescence polarization 
assay, have been developed and optimized to test the rescue of DNA-binding of the 
double-mutation variant. Furthermore, our collaborator is currently developing an in vivo 
assay to examine the rescue in living Chlamydia cells. Recently, a shuttle vector based 
system has been discovered to allow a tight control of target gene expression (151). 
Utilizing this shuttle vector to transform Chlamydia cells, we can express the ChxR 
double-mutation variant in Chlamydia cells that harbor a reporter gene under control of a 
ChxR-specific promoter, and monitors reporter gene expression upon the addition of the 
hit compounds. By coupling the rescue of ChxR structure to transcriptional activation, 
this assay provides a straightforward readout of the modulation of ChxR cellular function 
by small molecules. One major advantage of this in vivo assay is that the rescue of one 
single ChxR molecule leads to multiple events of DNA transcription, and this 
amplification of signal may be able to detect the rescue by compounds with either low 
binding affinity or weak partial agonistic effect, which may have been difficult to 
conclusively demonstrate in the proposed biochemical assays. 
The usage of ROCS as a virtual screening tool is also rather unconventional in 
this study: the ROCS software was originally developed as a ligand-based screening tool, 
for using a known drug lead to identify other potentially active compounds with similar 
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volume and shape. The preliminary results from this study suggest that ROCS is also a 
suitable tool for matching small molecules to constellations of disconnected atoms arising 
from multiple cavity-forming mutations. 
The preliminary results in this study provide a thorough evaluation of the 
generalized chemical rescue of structure, and strongly suggest the feasibility of 
employing chemical rescue of structure using multiple mutations. Accordingly, we expect 
that the insights offered here will enable rational design of a variety of new protein 
switches that utilizing diverse protein scaffold through this approach. In parallel, this 
methodology can also be utilized in the converse direction: rather than screen for a 
compound that matches some pre-selected constellation, we will instead screen for a 
constellation that matches our pre-selected compound of interest, which enables the 
design of selective sensor proteins to certain small molecules, especially those for which 









Chapter IV.  
Identifying inhibitors of the Musashi-1 protein-RNA interaction  
by hotspot mimicry 
 
Abstract 
RNA-binding proteins (RBPs) are key regulators of post-transcriptional gene 
expression. This makes understanding and controlling interactions between RBPs and 
their cognate RNAs critical for decoding mechanisms that underlie many important 
biological processes. Small-molecule inhibitors of specific RBPs would be extremely 
useful, but conventional approaches to design nucleoside analogues or allosteric ligands 
are not suitable for targeting the majority of RBPs. Drawing inspiration from inhibitors of 
protein-protein interactions, here we develop a strategy that entails extracting a “hotspot 
pharmacophore” from the structure of a protein-RNA complex, then using this as a 
template for ligand-based screening. For a first application of this approach we have 
selected the RNA-binding protein Musashi-1 (Msi1), a stem cell marker that positively 
regulates the Notch and Wnt signaling pathways, promotes cell cycle progression, and is 
upregulated in many cancers. Using this “hotspot mimicry” strategy we identified 
compounds that match the hotspot pharmacophore from the Msi1 / RNA complex, 
enabling development of novel inhibitors of the Musashi-1 / NUMB mRNA interaction 
that are active in both biochemical and cell-based assays. This study extends the 
paradigm of “hotspots” from protein-protein complexes to protein-RNA complexes, 
supports the “druggability” of RNA-binding protein surfaces, and represents the first 
example of a rationally-designed small-molecule that inhibits a non-enzymatic RNA-
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binding protein without relying on allostery. Owing to its simplicity and generality, we 
anticipate that the same approach may be used to develop inhibitors of many other RNA-
binding proteins as well, thus enabling design of a broad new class of chemical tools and 
potential starting points for novel therapeutic agents. 
Introduction 
RNA-binding proteins (RBPs) play crucial roles in diverse cellular processes. 
They regulate the life cycle of mRNAs by controlling splicing, polyadenylation, stability, 
localization and translation, and also modulate function of non-coding RNAs (152). 
Mammalian proteomes are thought to include upwards of 800 RBPs (153, 154), 
corresponding to both RNA-processing enzymes and non-enzymatic RNA-binding 
proteins. In light of the broad range of functions carried out by RBPs, the goal of this 
study is to devise a general and robust strategy for designing chemical tools that will 
allow precise manipulation of the interactions between RBPs and their cognate RNAs. 
We expect that such tools will help unravel the mechanisms of important biological 
processes controlled by RBPs, and may also serve as a starting point to validate RBPs as 
targets for therapeutic intervention (155-157). 
To date, there exist few classes of compounds that target protein-RNA 
interactions. Inhibitors of certain RBPs have been identified via high throughput 
screening (158, 159), including one series from virtual screening that competes with 
double-stranded RNA for binding to toll-like receptor 3 (160), and a number of 
compounds have been reported that disrupt binding by interacting with the RNA rather 
than with the RBP (71, 72). Among rationally designed small-molecule inhibitors that 
target RBPs, however, all examples reported to date can be categorized into two general 
 96 
classes. The first class is comprised of nucleoside analogues, such as anti-HIV-1 NRTIs, 
that mimic the chemical structures of natural-occurring nucleosides (61-63) and rely on 
enzymatic processing by their targets to form covalent adducts (161). While nucleoside 
analogues can be straightforward to design, the inability of these molecules to provide 
sufficient binding affinity or selectivity without covalent linkage precludes this strategy 
from being extended to non-enzymatic RBPs. The second class of compounds is 
comprised of allosteric inhibitors, such as anti-HIV-1 NNRTIs, that bind to secondary 
sites on the protein target and shift its conformation to an inactive state (63, 69, 70). In 
principle, allosteric inhibitors could be used to target both enzymatic and non-enzymatic 
RBPs; in practice, however, challenges associated with both identifying allosteric sites 
and then finding small molecules to complement these sites has limited the general utility 
of this approach to all but a few cases. Collectively, the fact that these RNA-binding 
protein surfaces are not thought to have evolved to bind any small-molecule makes them 
a “non-traditional” class of drug target. The relatively flat and polar nature of protein 
surfaces in this class typically leads to poor performance by structure-based virtual 
screening (docking) approaches (33), and given the lack of a known small-molecule 
binding partner it is even unclear a priori that such protein surfaces are suitable for 
inhibition by any small-molecule ligand at all (162). 
Here, we present a new approach for rationally designing small-molecule 
inhibitors of RBPs. We draw inspiration from a related class of “non-traditional” drug 
targets, protein-protein interfaces. In a protein-protein complex, each of the individual 
interfacial residues typically do not contribute equally to the energetics of binding; rather, 
the majority of the binding affinity derives from a small number of “hotspot” residues 
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(38-40). This observation, in turn, motivated several groups to mimic these key 
interactions when designing small-molecule inhibitors (43, 46, 48, 163). In this study, we 
take the “hotspot” paradigm and extend it to protein-RNA interactions. 
Our approach entails identifying the chemical moieties of a given RNA that 
contribute critical interactions to a particular protein-RNA complex, and then identifying 
small molecules that recapitulate the precise geometrical arrangement of these moieties. 
Our underlying hypothesis is that compounds capable of mimicking the three-
dimensional structure of the RNA “hotspot” will also mimic the energetically dominant 
interactions in the protein-RNA complex, using a much smaller chemical scaffold. By 
establishing a new method for reusing these protein-RNA interactions, we circumvent the 
challenging problem of needing to design interactions that target a flat, polar protein 
surface. 
Materials and Methods 
PDB structures used in calculations 
The calculations that led to selection of R1-R12 were carried out using model 1 of 
the NMR structure of Musashi-1 bound to RNA (PDB ID 2RS2). 
Building hotspot pharmacophores 
Hotspot pharmacophores were built using a dedicated protocol implemented in 
the Rosetta software suite (77), and is freely available for academic use 
(www.rosettacommons.org).  
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To select deeply buried RNA bases, the solvent accessible surface area (SASA) of 
each base in the RNA was calculated in the presence and absence of the protein. A base 
was carried forward if the change in SASA upon complexation was greater than a preset 
cutoff value (46.81 Å2 for adenine, 31.09 Å2 for cytosine, 45.06 Å2 for guanine and 52.66 
Å2 for uracil); these values correspond to the median values of protein-RNA complexes in 
the PRIDB database. 
Polar groups from the RNA that participate in intermolecular hydrogen bonding 
(as defined using the Rosetta energy function) are also included. 
The Rosetta command line used to carry out this step is as follows: 
get_rna_pharmacophore_with_water.macosgccrelease -input_rna xxx_rna.pdb -
input_protein xxx_protein.pdb 
 
The resulting interaction maps are then clustered using a modified version of 
Kruskal’s minimum spanning tree algorithm. We first build a complete graph, in which 
vertices are the ring moieties, and the edge weights are the Euclidean distances between 
vertices. Then we take edges in ascending order and cluster the end vertices of that edge 
if no cycle would be caused. We halt the clustering when the distance is greater than a 
user-specified cutoff value (default 5.0 Å). The donor/acceptor atoms are then assigned to 
the closest ring moieties if the distance is less than another user-specified value (default 
5.0 Å). Finally, we output the pharmacophore templates if the cluster contains at least 
two ring moieties. The Kruskal clustering code is also implemented in Rosetta, and is 
carried out as follows: 
cluster_pharmacophore.macosgccrelease –input xxx_rna.pdb –ring_cutoff xxx –
da_cutoff xxx 
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Identifying complementary ligands 
We used ROCS to screen large libraries for compounds that match the hotspot 
pharmacophore. We downloaded the standard ‘drugs-now’ subset of ~7 million 
molecules from ZINC database for screening (150). We generated up to 100 conformers 
for each molecule in the database using OMEGA (164-166). We screened the database 
using the hotspot pharmacophore (using default ROCS parameters), and carried forward 
the top 500 compounds ranked by 'TanimotoCombo' score. We then aligned these back to 
the protein using the hotspot pharmacophore, then carried out a gradient-based fullatom 
minimization of the complex using the Rosetta energy function (77). The top-scoring 
compounds were visually inspected and selected for experimental validation based on 
cost and availability. 
Predicting target selectivity 
Hotspot pharmacophores were extracted from each protein-RNA complex in the 
“RB344” dataset, which contains a non-redundant set of 344 protein-RNA complexes 
from the PDB extracted in March 2013. The dataset was retrieved from the Protein-RNA 
Interface Database (PRIDB) v2.0 (http://pridb.gdcb.iastate.edu/download/RB344.txt). 
Conformers for each compound were generated by OMEGA using the following 
command line: 
omega2 -in xxx.pdb -strictatomtyping false -strictstereo false -strictfrags 
false -searchff mmff94s -buildff mmff94s -maxconfs 500 
 
For a given compound, we then used ROCS to screen conformers of this molecule 
against the library of hotspot pharmacophores using the following command line: 
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rocs -dbase conformer_ensemble.pdb -query hotspot.pdb -oformat pdb –rankby 
FitTverskyCombo  
Synthesis of R12 derivatives : overview 
All air- and moisture-sensitive reactions were carried out in flame- or oven-dried 
glassware under argon atmosphere using standard gastight syringes, cannula, and septa. 
Stirring was achieved with oven-dried magnetic stir bars. Flash column chromatography 
was performed with SiO2 from Sorbent Technology (30930M-25, Silica Gel 60A, 40−63 
µm) or by using an automated chromatography instrument with an appropriately sized 
column. Thin layer chromatography was performed on silica gel w/UV254 plates 
(1624126, Sorbent Technologies). 1H and 13C NMR spectra were recorded on instruments 
operating at 400 or 500 MHz and 100 or 126 MHz, respectively. High-resolution mass 
spectrometry (HRMS) spectra were obtained on an ESITOF mass spectrometer. The 
analytical method utilized a Waters Aquity BEH C18 column (2.1 × 50 mm, 1.7 µm) 
eluting with a linear gradient of 95% water (modified to pH 9.8 through addition of 
NH4OH) to 100% CH3CN at 0.6 mL/min flow rate where purity was determined using 
UV peak area at 214 nm. 
Synthesis of specific intermediates / derivatives is described in detail in the 







Figure 4.1: Synthesis of R12 derivatives. (A) Chemical structures of all derivatives 
R13-R17. (B) Scheme leading to synthesis of all derivatives R13-R17 except R15. 
Reagents and conditions: (i) Pd2(dba)3, t-BuONa, BINAP, 80 ϒC, toluene, BocCOREH, 
59-91%. (ii) Dioxane, HCl, >95% yield. (iii) Aqueous NaCO3, CH2Cl2, >95%. (iv) 
CH3CN,  2-chloroquinazolin-4-amine, 180 ϒC, MW, 58-71%. (C) Scheme leading to 
synthesis of R15. Reagents and conditions: (v) DIEA, CH3CN, 96%. (vi) NaH, THF, 






Synthesis of R12 derivatives : general procedure #1 
 
Following a modified procedure outlined by Do et al. (167), a mixture of tert-
butyl 4-aminopiperidine-1-carboxylate (0.85 g, 4.22 mmol), 3,5-dibromopyridine (1.0 g, 
4.22 mmol) tris(dibenzylideneacetone)dipalladium(0) (0.077 g, 0.084 mmol), (±)-2,2'-
bis(diphenylphosphino)-1,1'-binaphthalene (0.11 g, 0.17 mmol) and sodium-t-butoxide 
(0.61 g, 6.33 mmol) in toluene (30.2 mL) was heated to 80 °C for 16 h, then the reaction 
mixture was allowed to cool to ambient temperature, diluted with ether (100 mL) and 
washed with brine (3×30 mL). The organic layer was dried over MgSO4, filtered and 
concentrated under vacuum. The residue was purified by silica gel chromatography (50% 
EtOAc in hexanes, Rf = 0.5) to afford the title compound tert-butyl 4-((5-bromopyridin-
3-yl)amino)piperidine-1-carboxylate (879.8 mg, 2.47 mmol, 59% yield) as a white solid. 
1H NMR (400 MHz, CDCl3) δ 8.22 (d, J = 2.6 Hz, 1H), 8.11 (d, J = 1.9 Hz, 1H), 7.31 
(dd, J = 2.6, 1.9 Hz, 1H), 4.55 (s, br. 1H), 3.70 – 3.60 (m, 3H), 2.97 – 2.90 (m, 2H), 2.14 
– 2.03 (m, 2H), 1.60 – 1.49 (m, 2H), 1.47 (s, 9H).  13C NMR (101 MHz, CDCl3) δ 
155.10, 147.64, 140.51, 136.65, 124.72, 120.81, 47.51, 47.42, 31.88, 28.40. 
Synthesis of R12 derivatives : general procedure #2 
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To a solution of tert-butyl 4-((5-bromopyridin-3-yl)amino)piperidine-1-
carboxylate (433.5 mg, 1.22 mmol) in dichloromethane (9 mL), was added hydrogen 
chloride in dioxane (15.2 mL, 60.8 mmol).  The reaction was stirred at rt for 16 h. 
Solvents were removed to give a white solid. Yield: 445.0 mg, 100%. 1H NMR (400 
MHz, MeOD) δ 8.53 (d, J = 2.4 Hz, 1H), 8.38 – 8.31 (m, 2H), 4.19 – 4.10 (m, 2H), 3.83 
– 3.58 (m, 3H), 3.53 – 3.47 (m, 1H), 3.26 – 3.14 (m, 2H), 2.26 – 2.17 (m, 2H), 1.84 – 
1.73 (m, 2H).  13C NMR (101 MHz, MeOD) δ 150.00, 132.59, 131.09, 127.98, 123.69, 
73.59, 72.48, 62.23, 46.60, 43.84. 
Synthesis of R12 derivatives : general procedure #3 
 
To a solution of 5-bromo-N-(piperidin-4-yl)pyridin-3-amine dihydrochloride 
(200.0 mg, 0.55 mmol) in methanol (4 mL), was added sodium carbonate (174.0 mg, 1.64 
mmol).  Solvent was removed and residue was extracted with DCM. DCM was dried 
over MgSO4 and evaporated to dryness to give a light-yellow oil. Yield: 81.0 mg, 58%. 
1H NMR (400 MHz, CDCl3) δ 8.20 (d, J = 2.6 Hz, 1H), 8.06 (d, J = 1.9 Hz, 1H), 7.28 
(dd, J = 2.6, 1.9 Hz, 1H), 3.82 – 3.56 (m, 3H), 2.93 – 2.79 (m, 3H), 1.97 – 1.86 (m, 2H), 
1.50 – 1.43 (m, 3H).  13C NMR (101 MHz, CDCl3) δ 147.78, 140.25, 136.61, 124.48, 
120.80, 48.22, 47.37, 35.15.  HRMS (m/z): calcd for C10H14BrN3 (neutral M+H) 
255.0371; found 255.0379. 
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Synthesis of R12 derivatives : general procedure #4 
 
To a solution of 2-chloroquinazolin-4-amine (28.4 mg, 0.16 mmol) and 5-bromo-
N-(piperidin-4-yl)pyridin-3-amine (81.0 mg, 0.32 mmol) in acetonitrile (2 mL) was 
heated at 180 °C for 1 h under microwave irradiation. The material was purified via 
reverse phase combiflash first, followed by further purification via silica gel 
chromatography (DCM/MeOH = 10:1, Rf = 0.3) to give 2-(4-((5-bromopyridin-3-
yl)amino)piperidin-1-yl)quinazolin-4-amine (36.4 mg, 0.091 mmol, 58% yield) as a 
white solid. 1H NMR (400 MHz, CDCl3) δ 8.24 (d, J = 2.6 Hz, 1H), 8.12 (d, J = 1.9 Hz, 
1H), 7.65 – 7.56 (m, 2H), 7.51 – 7.48 (m, 1H), 7.33 (t, J = 2.3 Hz, 1H), 7.16 – 7.12 (m, 
1H), 5.57 (s, br. 2H), 5.01 (s, br. 1H), 4.23 – 4.14 (m, 1H), 3.72 – 3.62 (m, 2H), 3.07 – 
3.00 (m, 2H), 2.25 – 2.20 (m, 2H), 1.71 – 1.56 (m, 2H). 13C NMR (101 MHz, CDCl3) δ 
162.1, 158.5, 152.3, 147.8, 140.4, 136.7, 133.4, 125.6, 124.6, 121.9, 121.5, 120.8, 110.4, 
47.5, 47.3, 31.9. HRMS (m/z): calcd for C18H20BrN6 (neutral M+H) 399.0933; found 
399.0900. 
Synthesis of R12 derivatives : specific compounds 
 
Synthesized by using general procedures #1, #2 and then #3.  1H NMR (400 MHz, 
DMSO-d6) δ 8.35 (d, J = 2.6 Hz, 1H), 8.15 – 8.02 (m, 4H), 7.72 (t, J = 2.2 Hz, 1H), 3.92 
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(d, J = 13.5 Hz, 2H), 3.25 (d, J = 12.5 Hz, 1H), 2.97 – 2.84 (m, 2H), 1.95 (d, J = 10.8 Hz, 
2H), 1.57 (qd, J = 12.2, 4.1 Hz, 2H).  HRMS (m/z): calcd for C10H14BrN3 (neutral M+H) 
255.0371; found 255.0366. 
 
Synthesized using general procedure 4 by reacting 2-chloroquinazolin-4-amine 
(0.036 g, 0.203 mmol) and 5-bromo-N-(piperidin-4-yl)pyridin-3-amine (.078 g, 0.305 
mmol) to give 2-(4-((5-bromopyridin-3-yl)amino)piperidin-1-yl)quinazolin-4-amine 
(.062 g, 0.155 mmol, 76 % yield) 1H NMR (400 MHz, Acetone-d6) δ 7.97 (d, J = 2.5 Hz, 
1H), 7.88 (dd, J = 8.1, 1.4 Hz, 1H), 7.78 (d, J = 1.9 Hz, 1H), 7.47 (ddd, J = 8.4, 6.8, 1.4 
Hz, 1H), 7.30 (dd, J = 8.5, 1.3 Hz, 1H), 7.17 (t, J = 2.2 Hz, 1H), 7.00 (ddd, J = 8.2, 6.8, 
1.2 Hz, 1H), 5.38 (d, J = 8.1 Hz, 1H), 4.83 – 4.66 (m, 2H), 3.63 (tdd, J = 6.5, 4.2, 2.4 Hz, 
1H), 3.08 (ddd, J = 13.8, 11.5, 2.7 Hz, 2H), 1.45 – 1.30 (m, 2H).  13C NMR (101 MHz, 
Acetone) δ 206.12, 163.36, 159.98, 153.94, 146.20, 138.11, 135.70, 133.34, 126.43, 
123.77, 121.26, 120.48, 111.01, 54.95, 50.64, 43.27, 32.60, 30.41, 30.22, 30.03, 29.83, 




Synthesized using general procedure 4 by reacting 2-chloroquinazolin-4-amine 
(0.045 g, 0.248mmol) and 1-(5-bromopyridin-3-yl)-1,4-diazepane (168) (0.127 g, 0.496 
mmol) to give 2-(4-(5-bromopyridin-3-yl)-1,4-diazepan-1-yl)quinazolin-4-amine 
(0.067g, 0.168 mmol, 68% yield) 1H NMR (400 MHz, Chloroform-d) δ 8.05 (d, J = 2.7 
Hz, 1H), 7.92 (d, J = 1.7 Hz, 1H), 7.57 – 7.45 (m, 3H), 7.13 – 7.01 (m, 2H), 4.10 – 4.00 
(m, 2H), 3.72 (t, J = 6.2 Hz, 2H), 3.64 (t, J = 5.3 Hz, 2H), 3.49 (t, J = 6.2 Hz, 2H), 2.10 
(t, J = 6.2 Hz, 2H).  13C NMR (101 MHz, CDCl3) δ 161.72, 158.08, 144.71, 137.58, 
133.16, 132.56, 125.72, 121.87, 121.24, 121.14, 120.16, 109.69, 77.36, 77.04, 76.72, 
53.75, 49.89, 47.84, 46.61, 46.22, 24.37.  HRMS (m/z): calcd for C18H20BrN6 (neutral 
M+H) 399.0864; found 399.0855. 
 
Synthesized using general procedure 4 by reacting 2-chloroquinazolin-4-amine 
(0.022 g, 0.124 mmol) and 1-(5-bromopyridin-3-yl)piperazine (168) (.03 g, 0.124 mmol) 
to give 2-(4-(5-bromopyridin-3-yl)piperazin-1-yl)quinazolin-4-amine (.031 g, 0.080 
mmol, 64.9 % yield). 1H NMR (400 MHz, Chloroform-d) δ 8.26 (d, J = 2.6 Hz, 1H), 8.14 
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(d, J = 1.9 Hz, 1H), 7.63 – 7.48 (m, 3H), 7.34 (dd, J = 2.6, 1.9 Hz, 1H), 7.13 (ddd, J = 
8.1, 6.8, 1.3 Hz, 1H), 4.42 – 3.94 (m, 4H), 3.58 – 3.11 (m, 4H).  13C NMR (126 MHz, 
CDCl3) δ 161.68, 158.76, 152.60, 147.97, 141.01, 136.62, 133.35, 126.08, 124.64, 
121.76, 121.62, 120.86, 109.91, 48.26, 43.48.  HRMS (m/z): calcd for C17H17BrN6 
(neutral M+H) 384.0698; found 384.0709. 
 
5-bromopyridin-3-amine (0.3 g, 1.734 mmol) was dissolved in acetonitrile and the 
reaction mixture was cooled to 0 °C.  N,N'-Diisopropylethylamine (0.636 ml, 3.65 mmol) 
was added dropwise.  Then, 1-chloro-2-isocyanatoethane (0.156 ml, 1.825 mmol) was 
added dropwise.  The reaction was allowed to stir for 16 hours.  The reaction was 
quenched with water, washed with brine, dried with sodium sulfate and then concentrated 
en vacuo and then purified via normal phase chromatography (ethyl acetate/hexanes) to 
give 1-(5-bromopyridin-3-yl)-3-(2-chloroethyl)urea (.49 g, 1.759 mmol, 96 % yield)1H 
NMR (400 MHz, DMSO-d6) δ 9.09 (s, 1H), 8.44 (d, J = 2.2 Hz, 1H), 8.27 (t, J = 2.2 Hz, 
1H), 8.23 (d, J = 2.1 Hz, 1H), 6.67 (t, J = 5.9 Hz, 1H), 3.67 (t, J = 6.1 Hz, 2H), 3.43 (q, J 
= 6.1 Hz, 2H).  13C NMR (101 MHz, DMSO) δ 149.09, 142.29, 137.94, 130.73, 126.34, 




In a round bottomed flask, 1-(5-bromopyridin-3-yl)-3-(2-chloroethyl)urea (.3 g, 
1.077 mmol) was dissolved in THF, a stir bar was added and the reaction mixture was 
cooled to 0 °C.  To the reaction mixture sodium hydride (0.078 g, 3.23 mmol) was added 
slowly.  The reaction was allowed to slowly warm to room temperature and allowed to 
continue stirring for 16 hours.  The reaction was cooled to 0 °C and then quenched with 
the dropwise addition of water.  More water was added, then extracted three times with 
ethyl acetate, washed twice with water, twice with brine and then dried with sodium 
sulfate and concentrated en vacuo.  The crude residue was then purified via normal phase 
chromatography (Methanol/DCM) to give 1-(5-bromopyridin-3-yl)imidazolidin-2-one 
(.217 g, 0.896 mmol, 83 % yield).  1H NMR (400 MHz, DMSO-d6) δ 8.72 – 8.64 (m, 
1H), 8.34 (t, J = 2.2 Hz, 1H), 8.32 – 8.24 (m, 1H), 7.32 (s, 1H), 3.96 – 3.86 (m, 2H), 3.45 
(ddd, J = 8.9, 6.8, 1.1 Hz, 2H).  13C NMR (101 MHz, DMSO) δ 158.78, 142.26, 136.70, 
125.52, 119.66, 43.90, 36.92.  HRMS (m/z): calcd for C8H8BrN3O (neutral M+H) 
240.9885; found 240.9851.   
 
To a dried round bottomed flask was added 1-(5-bromopyridin-3-yl)imidazolidin-
2-one (.1 g, 0.413 mmol), THF and a stir bar.  The mixture was cooled to 0 °C.  Then, 
sodium hydride (0.030 g, 1.239 mmol) was added slowly.  The mixture was allowed to 
stir for 30 minutes.  Then, 2-chloroquinazolin-4-amine (0.074 g, 0.413 mmol) was added.  
The reaction was allowed to warm to room temperature slowly and then continue stirring 
for 12 hours.  The reaction was quenched with water, extracted three times with ethyl 
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acetate, washed with brine, dried with sodium sulfate and then concentrated en vacuo.  
The crude residue was purified via normal phase chromatography 
(Methanol/dichloromethane) and tehn reverse phase chromatography (water pH = 9, 
acetonitrile) to yield 1-(4-aminoquinazolin-2-yl)-3-(5-bromopyridin-3-yl)imidazolidin-2-
one (.11 g, 0.286 mmol, 69.1 % yield). 1H NMR (400 MHz, DMSO-d6) δ 8.83 (d, J = 2.3 
Hz, 0H), 8.50 – 8.38 (m, 1H), 8.23 – 8.13 (m, 0H), 7.82 (s, 1H), 7.70 (ddd, J = 8.4, 6.9, 
1.4 Hz, 0H), 7.57 – 7.51 (m, 0H), 7.34 (ddd, J = 8.3, 7.0, 1.3 Hz, 0H), 4.15 (dd, J = 9.2, 
6.6 Hz, 1H), 4.04 – 3.92 (m, 1H).  13C NMR (101 MHz, DMSO) δ 162.52, 154.72, 
152.23, 150.58, 143.31, 137.97, 137.47, 133.05, 126.49, 126.33, 123.56, 119.65, 111.96, 
102.47, 41.66, 40.64.  HRMS (m/z): calcd for C16H13BrN6O (neutral M+H) 384.0334; 
found 384.0340. 
Model building of R12 derivatives 
Conformers of R13-R17 were generated using OMEGA. For each compound, we 
aimed to generate sample likely conformers that optimally matched the ring geometry in 
the hotspot pharmacophore. To achieve this, we used the CHARMM software (169) to 
carry out a biased energy minimization of the compound (in the absence of the protein). 
We implemented the bias using a harmonic constraint applied to the Cartesian 
coordinates of certain atoms, centered at the position of the corresponding atom of the 
hotspot pharmacophore (C4,C5,N7,C8 and N9 on Adenine106 and N1, C2, N3, C4, C5, 
C6, N6, N7, C8 and N9 on Guanine107) and with a scale factor of 100 (this scale factor 
is related to the force constant in a way that depends on the mass of individual atoms). 
The residue topology file and parameter file for the compounds required by CHARMM 
minimization were obtained from CHARMM-GUI (170). 
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Through this minimization of OMEGA conformers, we generated models of the R12 
derivatives that maintain the ring geometry in the hotspot pharmacophore but contain a 
variety of geometries in the linker region. Since the resulting conformers match the 
hotspot pharmacophore, they are already aligned to the structure of the Msi1-RNA 
complex. We concluded by selecting the best model on the basis of protein-ligand 
interaction energy using the fullatom Rosetta energy function (77). 
Expression and purification of Msi1 
A gene encoding human Msi1 RBD1 domain was subcloned as a fusion protein 
with an N-terminal 6xHis-tagged streptococcal GB1 domain and a tobacco etch virus 
(TEV) protease site. The expression plasmid was transformed into Escherichia coli 
BL21(DE3) pLysS, then a 5 ml overnight starter culture was used to inoculate a 1 L 
culture of LB media. Cells were grown at 37 ºC to an OD600 of 0.6–0.8 and were 
induced with 1 mM IPTG overnight at 15 ºC. The induced cells were resuspended in lysis 
buffer (50 mM Tris, 150 mM NaCl, 5 mM imidazole pH 8.0) and sonicated for 10 
minutes (Fisher Scientific Sonic Dismembrator Model 100). The cell lysates were then 
centrifuged at 15,000g for 30 min. The GB1-RBD1 remained in the supernatant, which 
was purified by HPLC affinity chromatography with Ni-chelated Sepharose Fast Flow 
Resin (GE Healthcare), followed by a HiLoad 16/60 Superdex 75 gel filtration column 
(GE Healthcare). GB1 tag was digested with TEV protease (1 OD280 of TEV per 5 OD280 
of fusion protein) in reaction buffer (50 mM Tris-HCl, 0.5 mM EDTA and 1mM DTT pH 
8.0). All protein concentrations were determined with reference to bovine albumin 
standards using Bradford assays. 
 112 
Fluorescence polarization competition assays 
RNA oligonucleotides were ordered from Integrated DNA Technologies 
(Coralville, IA) and dissolved in TE buffer (10 mM Tris-HCl, 1 mM EDTA pH 8.0): 
sequences are included in Table 4.1. To measure the dissociation constant of Msi1 RBD1 
and RNA binding, a fixed concentration (2 nM) of fluorescein-labeled RNA (FC-NUMB, 
Table 4.1) and increasing concentrations of Msi1 RBD1 (1 nM to 1000 nM) were mixed 
in binding assay buffer (20 mM HEPES, 150 mM NaCl, 0.05% F-68 pH 7.4). 
Fluorescence intensities were measured in replicate on the BioTek Synergy 2 plate reader 
(Winooski, VT) and the fluorescence polarization value (FP) was calculated by the 
following equation: 
𝐹𝑃 =
𝐼∥   −   𝐼!
𝐼∥ +   𝐼!
 
The dissociation constant (KD) was fit using Prism (v 6.0e, GraphPad Software, 
Inc., La Jolla, CA), with the Hill coefficient fixed at n=1 as follows: 





To test the contribution to binding affinity of each base in the NUMB RNA 
sequence, we purchased five oligos that each harbor an abasic site at a different position, 
as well as the corresponding wild-type (aNUMB0-5, Table 4.1). Ki values were then 
determined from a competition experiment in which serial dilution of unlabeled aNUMB 
oligos (5 nM – 5000 nM) were added to compete against a fixed concentration (2 nM) of 
fluorescein-labeled RNA (FC-NUMB) for binding to a fixed concentration of Msi1 
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RBD1 (75 nM). The Ki value was determined by fitting with Prism to the “Binding – 
Competitive – One site – Fit Ki” model (171). 
To examine the displacement of FC-NUMB by R13, we performed the same 
competition assay using R13 as a competitor (5 µM – 150 µM). The Ki value was 



















Table 4.1: Sequences of RNA oligonucleotides used in this study. “FC” refers to the 
fluorescein label, and “x” refers to an abasic site (i.e. internal RNA spacer site). After 
validation to ensure binding to Msi1 RBD1 (Figure 4.11), the FC-NUMB construct was 
used in fluorescence competition assays (Figure 4.2D, Figure 4.4G). 
 
Name Sequence 
FC-NUMB 5’- F-GUAGU -3’ 
NUMB 5’- GUAGU -3’ 
NUMBa0 (WT) 5’- UGUAGUU -3’ 
NUMBa1 (G104x) 5’- UxUAGUU -3’ 
NUMBa2 (U105x) 5’- UGxAGUU -3’ 
NUMBa3 (A106x) 5’- UGUxGUU -3’ 
NUMBa4 (G107x) 5’- UGUAxUU -3’ 









Surface plasmon resonance 
Binding between Msi1 RBD1 and each compound were analyzed by SPR using a 
Biacore 3000 optical biosensor (GE Healthcare). GB1-tagged Msi1 RBD1 was covalently 
immobilized by amine-coupling on a carboxymethylated dextran sensor chip (CM-5, GE 
Healthcare). Amine-coupling reactions for immobilization of proteins were performed at 
approximately 5 µg⁄mL in 10 mM sodium acetate buffer pH 5.5 injected at 5 µL⁄ min 
until 8400 response units (RU) were immobilized. An unmodified flow cell was used as 
reference. An unrelated protein, human Mcl-1, was immobilized on another flow cell and 
used to subtract out the response from unspecific binding. 
All SPR runs were performed at 25 ºC using a flow rate of 50 µL/min in running 
buffer (HEPES buffered saline with 0.05% Tween-20 pH 7.4). Compounds were injected 
over sample and reference flow cells at a concentration of 50 µM in running buffer, for 
250 s. Following each injection, flow cells were regenerated with a 20 s injection of 1 M 
NaCl. 
SPR titration data were analyzed by using Scrubber 2 software (Biologic) to zero, 
crop, align and subtract responses from the unmodified surface and average blank 
injections. Response from the Mcl-1 flow cell was also subtracted to remove the response 
from unspecific binding. 
Differential scanning fluorimetry (Thermofluor) 
Differential scanning fluorimetry (DSF) experiments were carried out using a 
standard protocol described by others (172). All experiments were carried out in a 
reaction volume of 25 µL, with 25 mM Tris-Cl pH 8.0, 120 mM NaCl, 2% DMSO, and 
100x-diluted Sypro Orange dye (Invitrogen). Multiple concentrations of GB1-tagged 
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Msi1 RBD1 (ranging from 1 µM to 15 µM) were tested to identify the lowest 
concentration necessary to generate a smooth melting curve. For subsequent experiments, 
we used a concentration of 7.5 µM. 
This concentration of protein was incubated with varying concentrations of R13 
(ranging from 0.1 µM to 100 µM). Testing tubes were incubated in StepOnePlus™ Real-
Time PCR System (Applied Biosystems) and samples were heated from 25 ºC to 65 ºC 
gradually with 0.5% increase. The fluorescence emission was measured using filter for 
ROX (610 nm). 
The melting temperature (Tm) values were determined by taking the maximum of 
the first derivative of the raw fluorescence intensity with respect to temperature (172), 
using GraphPad Prism 5. ΔTm values were calculated by comparing the Tm of a 
particular R13 concentration to that of the DMSO control. 
Computational Approach 
Computational methods are implemented in the Rosetta software suite (77) unless 
otherwise indicated. Rosetta is freely available for academic use 
(www.rosettacommons.org), with the new features described here included in the 3.6 
release. 
Building “hotspot pharmacophores” 
While interfaces between RBPs and their cognate RNAs are mostly flat, 
complexes involving segments of single-stranded RNA often include a few interfacial 
nucleobases that are buried much more deeply than the others (Figure 4.2A); this uneven 
distribution is reminiscent of “hotspot” sidechains in protein-protein complexes (38, 39). 
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The protein has evolved to interact with these buried nucleobases through precise 
intermolecular aromatic stacking interactions and hydrogen bonding. 
We have developed an automated framework that distills the structure of a 
protein-RNA complex to a “hotspot pharmacophore,” which in turn can serve as a 
template for ligand-based screening. Our framework first picks out those RNA aromatic 
moieties that are deeply buried in the protein-RNA complex, as well as any RNA atoms 
involved in intermolecular hydrogen bonds to the protein or ordered water molecules 
(Figure 4.2B). Any polar atoms on the nucleobases that do not participate in hydrogen 
bonds are then replaced with carbon atoms, since those polar groups need not be carried 
forward into inhibitor design. This gives a broad spatial map of the protein-RNA 
interaction, which typically cannot be spanned by a single drug-like small molecule; we 
therefore clustered neighboring moieties, and advanced each cluster separately. Through 
this approach, we reduce the structure of the protein-RNA complex to a minimal “hotspot 
pharmacophore” that encapsulates the key interactions to be recapitulated by a small 









Figure 4.2: The hotspot mimicry approach. We demonstrate this approach by applying 
it to the Msi1 / NUMB mRNA interaction. (A) The structure of the Msi1 / RNA complex. 
The RNA (yellow and orange sticks denoting the backbone and the bases, respectively) 
wraps around the protein (green and grey spheres). Two adjacent bases, A106 and G107 
(magenta), are buried in a shallow pocket on the protein surface. (B) An interaction map 
is generated from the RNA in the complex, by collecting deeply buried bases (magenta) 
and atoms involved in intermolecular hydrogen bonds (acceptors shown in yellow, 
donors in green). (C) Components of the interaction map are clustered in space, and 
atoms that do not participate in hydrogen bonding are reverted to carbon atoms; this 
produces a “hotspot pharmacophore.” (D) The difference in binding free energy between 
an RNA harboring a single abasic site versus the wild-type NUMB mRNA, as determined 
through competition with a fluorescently-labeled RNA. Positive values indicate 
diminished binding when a given base is replaced with an abasic site, showing that A106 
and G107 contribute more than the other nearby bases to Msi1 / NUMB mRNA binding 
affinity. (E) The hotspot pharmacophore serves as a template for ligand-based screening. 
In this case we identified three classes of hit compound that mimic the three-dimensional 
features of the pharmacophore, as exemplified by the representatives shown here. (F) 
Superposition of the hotspot pharmacophore back onto the protein structure illustrates the 
interactions that should be captured by an ideal ligand: stacking against three aromatic 
sidechains, and four intermolecular hydrogen bonds. (G) Superposition of R12 onto the 
protein structure shows that this compound is expected to preserve the aromatic stacking, 






Identifying complementary ligands 
To identify such compounds, we used this hotspot pharmacophore as a template for 
carrying out ligand-based virtual screening. In order to facilitate rapid characterization of 
compounds emerging from our screen, we restricted our search to the ~7 million 
compounds in the ZINC database (150) that are both commercially available, and 
predicted to have drug-like physicochemical properties. We used OMEGA (OpenEye 
Scientific Software, Santa Fe, NM) (164-166) to build low-energy conformations of each 
compound, then ROCS (OpenEye Scientific Software, Santa Fe, NM) (173, 174) to align 
each conformation to our hotspot pharmacophore. For each of the top-scoring hits 
emerging from ROCS, we then used the aligned orientation to position the compound 
relative to the protein, and evaluated the interaction energy of the protein-ligand complex 
using the fullatom Rosetta energy function (77). 
Musashi-1, an RRM-containing protein 
The approach described above can, in principle, be applied to the structure of any protein-
RNA complex. As a first test, we selected a target from the most common and well-
studied of RNA-binding modules, the RNA-recognition motif (RRM) domain. Hundreds 
of structures of RRMs have been deposited in the Protein Data Bank, including more than 
fifty in complex with RNA (175). Collectively these structures show that RRMs adopt a 
conserved fold that packs two α-helices against one face of a four-stranded β-sheet; in 
most cases the opposite face of this β-sheet is then used to bind a single-stranded segment 
of RNA. Recognition of cognate RNA is usually driven by a cluster of three outward-
facing aromatic amino acids on this β-sheet, which often form stacking interactions with 
a pair of adjacent RNA bases (176). Accordingly, mutations to the protein that remove 
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these aromatic sidechains have been shown to disrupt binding in representative RRMs 
(176, 177), as has introduction of non-canonical bases to the RNA that alter the pattern of 
hydrogen bonding groups (178-180). Despite these shared features, however, the precise 
geometry of the dinucleotide pair in its complex with the RRM can differ very drastically 
across members of this family (176). 
Mammalian Musashi-1 (Msi1) recognizes its cognate RNAs through a pair of RRMs, 
RBD1 and RBD2 (181). Together these two domains bind to the 3’-UTR region of 
specific target mRNAs, including the mRNA encoding NUMB, and impede initiation of 
their translation (59, 60). NUMB mRNA encodes an inhibitor of Notch, so translational 
inhibition by Msi1 triggers Notch signaling and thus promotes self-renewal and cell 
survival (35, 60). Considering the role of Msi1 in stem cell maintenance and renewal, 
distrupting its RNA-binding ability may inhibit cancer stem cells that play a role in drug- 
and radioresistance, and thus serve as an attractive potential anti-tumor strategy (182). 
Results 
Computational screening against Msi1 RBD1 
We applied our “hotspot mimicry” approach to the Musashi-1 RBD1 / NUMB 
mRNA complex (181), and found a single hotspot pharmacophore derived from an 
adjacent pair of buried nucleotides, Adenine106 and Guanine107 (Figure 4.2A). This 
pharmacophore captures both the aromatic stacking and the hydrogen bonding of the 
RNA hotspot through its inclusion of ring moieties and donor/acceptor positions, 
respectively (Figure 4.2C). To test whether these particular two bases indeed serve as a 
hotspot of the Msi1 RBD1 / RNA interaction, we used a fluorescence polarization 
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competition assay to measure the binding affinity of NUMB mRNA variants that lacked 
individual bases. Using this assay, we found that introduction of an abasic site at either of 
these two positions led to a marked decrease in binding to Msi1 RBD1 (Figure 4.2D). In 
contrast, introduction of an abasic site at other nearby positions affecting binding much 
less. Confirmation that A106 and G107 serve as hotspots bases for this interaction thus 
provided experimental evidence supporting the pharmacophore selection from our 
computational approach. 
We then used this pharmacophore as a template for virtual screening, and found 
that the 12 top-scoring hits could each be classified into one of three diverse chemotypes 
(Figure 4.3). While none of these scaffolds bear any obvious resemblance in chemical 
structure to a nucleobase pair, the overlap in three-dimensional shape and hydrogen 
bonding potential between the hotspot pharmacophore and the modeled conformation of 
each compound is immediately evident (Figure 4.2E). Despite this strong similarity, 
none of the 12 hit compounds recapitulated all four of the polar groups included in the 
hotspot pharmacophore, and only three hit compounds matched to three of the polar 
groups: R12, its close analog R4, and R7. The lack of hits that simultaneously match all 
four polar groups reflects a limit of the chemical space spanned by our screening library; 
we will discuss this in detail later. 
As expected, superposition of the hit compounds back onto the hotspot 
pharmacophore in the context of the protein-RNA complex confirmed that these ligands 
might preserve the favorable interactions of the dinucleotide pair. In particular, the ring 
moieties in the pharmacophore represent the stacking of nucleobases against Phe23, 
Phe65 and Phe96 of Msi1, while the hydrogen bonding atoms indicate polar contacts with 
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the sidechain of Lys21 and the backbones of Val94 and Phe96 of Msi1 (Figure 4.2F). 
Mimicry of these interactions through the hotspot pharmacophore allows the hit 
compounds to recapitulate these interactions, as exemplified by R12 (Figure 4.2G). In 
this model R12 adopts a similar three-dimensional geometry as the hotspot 


















Figure 4.3: The 12 initial hit compounds. The chemical structure is shown for each 
compound, as well as a three-dimensional model of each compound (cyan) superposed 





Biochemical characterization of computational hits 
We purchased each of the compounds corresponding to these 12 top-scoring hits 
(Figure 4.3). We used surface plasmon resonance (SPR) to directly test for binding of 
each compound to Msi1, by immobilizing recombinant human Msi1 RBD1 onto an SPR 
chip and then passing each compound over the chip at a concentration of 50 µM (see 
Materials and Methods). The sensorgram for R12 showed a kinetic profile consistent 
with binding to Msi1 RBD1 (Figure 4.4A); none of the other compounds exhibited this 
behavior (Figure 4.5). 
As noted earlier, only R12 and two other compounds matched as many as three polar 
groups in the hotspot pharmacophore; the lack of binding observed for the other 
compounds (at this concentration) may be attributable to the fact that they do not 
sufficiently recapitulate the interactions of the hotspot pharmacophore. While R7 
matched three polar groups, retrospective analysis of the structural model revealed that 
the imperfect alignment of the rings to the pharmacophore may have led to a steric clash 
with the protein (Figure 4.6). 
Interestingly, the R12 class was comprised of two compounds: R12 and R4. These 
compounds differ only in the position and identity of a single substituent: the R12 has a 
bromine atom at the meta position of the pyridine moiety, while R4 instead harbors a 
methyl group at the para position. Comparison of these compounds in the context of the 
protein partner immediately reveals a potential source for their differing responses in the 
SPR experiment: in our model, this methyl group of R4 forms a steric clash with the side 
chain of Leu31 on Msi1 that we had not initially recognized (Figure 4.4B); in contrast, 
the shifted position of the R12 substituent avoids this steric clash. This initial 
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(inadvertent) structure-activity experiment provides strong support for the structural 























Figure 4.4: Biochemical characterization and optimization of computational hit 
compounds. (A) Initial screening via surface plasmon resonance: representative 
sensorgrams for R12 and R4 are shown. The kinetic profile of R12 (red) is consistent 
with binding to Msi1, whereas that of its close analog R4 (blue) shows no evidence of 
binding. (B) Comparison between the predicted binding models of R12 and R4. The top 
scoring conformers of R12 (red) and R4 (blue) are transferred back to the protein by 
alignment to the hotspot pharmacophore. The model of R4 suggests its lack of binding 
may stem from a steric clash with Leu31, whereas R12 avoids this steric clash since this 
ring is substituted at a different position. (C) Chemical structures of R12 and one of its 
derivatives, R13, that replaces R12’s ester with a piperidine ring and a secondary aimine 
in the linker. (D) Model of R13 bound to Msi1, by alignment to the hotspot 
pharmacophore. R13 preserves the interactions of R12, but reduces flexibility of the 
linker and removes potential electrostatic repulsion with Msi1. (E) R13 shows kinetic 
profile consistent with reversible binding using surface plasmon resonance at the 
concentration of 50 µM. (F) R13 increases Msi1 melting temperature in a concentration-
dependent manner, providing evidence of their interaction in solution. (G) R13 competes 









Figure 4.5: Initial SPR screening. Surface plasmon resonance was used to test for 
binding of all 12 compounds, with immobilized Msi1 RBD1. At a concentration of 50 
µM, none of the compounds except for R12 showed a kinetic profile consistent with 
reversible binding. All sensorgrams shown have been reference-subtracted using a flow 







Figure 4.6: An inadvertent steric clash may explain the lack of binding by R7. (A) 
The rings in the model of R12 (yellow) are well-superposed with those of the hotspot 
pharmacophore (magenta), allowing for aromatic stacking with Msi1. (B) The relative 
positioning of the rings in the R7 (cyan) do not quite align with the hotspot 
pharmacophore (right side of this perspective). (C) This difference in the positioning of 




Optimization of R12 
Guided by this model, we next set out to improve the potency of R12. The limited 
chemical space in our screening library led to two undesirable features of this compound. 
First, the carbonyl oxygen in the ester linker of R12 is positioned in close proximity to 
the Phe96 backbone carbonyl of Msi1 (Figure 4.2F); beyond simply the lost opportunity 
for an intermolecular hydrogen bond, we expect electrostatic repulsion between these two 
negatively charged moieties. Second, the two ring systems of R12 are connected by a 
somewhat flexible linker; rigidifying this linker might reduce the conformational entropy 
lost upon binding. With these two motivations in mind, we designed and synthesized a 
panel of five new R12 derivatives, R13-R17 (Figure 4.1) (see Materials and Methods). 
Using our previous SPR assay, we find that all five derivatives exhibit kinetic 
profiles at 50 µM consistent with binding to Msi1 (Figure 4.4E, Figure 4.7). Below we 
will present further biochemical characterization of R13, a compound that met our design 
goals by replacing R12’s ester with a piperidine ring and a secondary amine in the linker 
(i.e. homopiperazine) (Figure 4.4C). Upon building models for each of the five R12 
derivatives in complex with Msi1, we find that the rigidified linker in each compound 
allows recapitulation of R12’s interactions while relieving the potential source of 
electrostatic repulsion; unfortunately however, none of the models include an additional 
hydrogen bond to Msi1 (Figure 4.4D, Figure 4.8). 
In order to confirm binding of R13 to Msi1 in an orthogonal assay, we used 
differential scanning fluorimetry (DSF / Thermofluor) to determine protein 
thermostability as a function of ligand concentration. We find that the melting 
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temperature of Msi1 increases upon addition of R13 in a dose-dependent manner 
(Figure 4.4F), up to a 3 ˚C increase in presence of 30 µM R13.  
Finally, we directly examined the ability of R13 to not simply bind Msi1, but also 
to inhibit its interaction with NUMB mRNA. We used a fluorescein-labeled RNA 
oligonucleotide corresponding to the Msi1 recognition sequence of NUMB, which 
exhibits an increase in polarization upon Msi1 binding (Figure 4.9). The subsequent 
addition of R13 is expected to lead to a decrease in polarization, if R13 competes with 
NUMB mRNA for Msi1 binding as designed. Indeed we observe this dose-dependent 
behavior (Figure 4.4G), and using the apparent binding affinity of the labeled RNA for 














Figure 4.7: SPR screening of R12 analogs. Surface plasmon resonance was used to test 
for binding of all five R12 analogs, with immobilized Msi1 RBD1. At a concentration of 
50 µM, all five showed a kinetic profile consistent with reversible binding. All 
sensorgrams shown have been reference-subtracted using a flow cell with an unrelated 











Figure 4.8: Models of R12 analogs in complex with Msi1. Structures were generated 
by building conformations of each compound that closely superpose with the rings of 





Figure 4.9: Binding of fluorescein-labeled RNA to Msi1. The polarization from the 
fluorescein tag increases upon addition of Msi1 RBD1, implying that the protein binds to 
the RNA. The analogous polarization change is not observed when Msi1 RBD1 is added 
to a mixture of fluorescein-labeled RNAs with random sequences (Table 4.1 in 








Predicting target selectivity 
Many RRM proteins recognize their target RNAs with high sequence specificity, 
through additional interactions outside the central RNA dinucleotide (176). Our mimicry 
of the Msi1 hotspot was predicated on recapitulating the interactions solely within this 
dinucleotide; we therefore sought to explore the target selectivity expected for these 
inhibitors by searching for potential off-target interactions. Staring with all the protein-
RNA complexes deposited in Protein Data Bank, we used our computational approach to 
extract the set of all hotspot pharmacophores in the PDB (see Materials and Methods). 
For a given compound of interest, we can then screen all conformers of this molecule 
against this “library” of hotspot pharmacophores (Figure 4.10A). The top-scoring hits in 
this experiment represent proteins that recognize their cognate RNAs through interaction 
patterns that can be recapitulated by the compound of interest, making these candidate 
proteins for off-target binding. We note that this large-scale experiment does not 
explicitly account for protein flexibility, which may enable further of off-target 
interactions. To demonstrate the variation in pharmacophore structure associated with 
typical protein fluctuations, we have included in our studies each member of the 
experimentally-derived Msi1-RNA NMR ensemble (181). 
We applied this analysis first to a series of hypothetical compounds, each one 
comprised of guanine and adenine attached by flexible linkers of varying lengths 
(Figure 4.10B). We find that each of these constructs can adopt a conformation that 
aligns well to the Msi1 hotspot pharmacophore, but they also undergo rearrangements 
that allow them to match many of the other hotspot pharmacophores in our library. This 
observation is unsurprising, since one would expect these artificial ligands to mimic 
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many guanine-adenine dinucleotide pairs with little consideration of their three-
dimensional arrangement. 
We next carried out the same analysis for R12 (Figure 4.10C) and each of the 
other hits from our initial computational screen (Figure 4.11A). Relative to the guanine-
adenine pairs, R12 lacks certain polar groups (those that do not participate in the Msi1 
pharmacophore). While this reduces R12’s potential for mimicking some of the off-target 
hotspot pharmacophores, we nonetheless find one alternate match with score comparable 
to that of Msi1, which is derived from a KH domain from the bacterial methyltransferase 
RsmE (Figure 4.10C, blue arrow). Notably, this off-target hotspot pharmacophore is 
recognized not because they bear strong resemblance to the Msi1 pharmacophore; rather, 
flexibility in the R12 linker allows it to match these alternate pharmacophores by 
adopting a different conformation (Figure 4.10C, blue boxes). 
Finally, we applied this analysis to R13 (Figure 4.10D) and each of the other R12 
derivatives (Figure 4.11B); we find that these match the Msi1 hotspot pharmacophore far 
better than any of the others extracted from the PDB. Constraint by the more rigid linker, 
R13 demonstrates much worse matching to the potential off-target pharmacophore for 
R12. This result suggests that the specific three-dimensional structure of the Msi1 hotspot 
pharmacophore, which is derived from the nucleobases of the buried adenine-guanine 
dinucleotides, may be sufficient to deliver selectivity into the matching compounds. To 
illustrate this point, we further examined another hotspot pharmacophore that is derived 
from an adenine-guanine pair in complex with a different RRM domain (Figure 4.12). 
Though the general domain topology and the binding site of the dinucleotides are similar 
in both RRMs, the detailed interaction of these dinucleotides is drastically different 
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(Figure 4.12A). Inheriting the uniqueness of Msi1 hotspot pharmacophore, R13 exhibits 
low structural similarity to the other adenine-guanine derived pharmacophore, which 
results in a potential steric clash to the binding site when transferred to the binding site of 
the other RRM domain (Figure 4.12B). 
While this experiment does not account for flexibility of any of the off-target 
proteins, we do note that R13 matches some of the other members of the Msi1 NMR 
ensemble better than the single structure that led to its design (red bar). This highlights 
the robustness of hotspot pharmacophore matching to small changes in protein structure, 
and suggests that protein flexibility is unlikely to lead to alternate hotspot 
pharmacophores that are preferred by R13. While further experimental evidence will be 
necessary to explicitly determine whether these compounds engage in unanticipated 
interactions with other RBPs, these results suggest that the increased rigidity of the R13 
linker makes it unable to access the alternate conformations that might allow R12 to 
mimic certain off-target pharmacophores. 
Collectively, these observations point to the uniqueness of the Msi1 hotspot 
pharmacophore with respect to the rest of the Protein Data Bank; while many other RBPs 
bind to a guanine-adenine pair, only Msi1 recognizes a guanine-adenine pair in precisely 
this geometry. Through the use of a rigid chemical scaffold that closely mimics the three-
dimensional geometry of the hotspot pharmacophore, we expect to achieve target 
selectivity that would not be possible by direct mimicry of chemical structure (i.e. by 




Figure 4.10: Computational prediction of potential off-target interactions. (A) We 
screened each conformer of a given ligand against a large set of hotspot pharmacophores 
derived from other protein-RNA complexes. Hits in this screen correspond to other 
proteins that recognize their cognate RNAs using interactions that could be mimicked by 
the compound of interest. (B) Application of this approach to a series of hypothetical 
compounds built by connecting adenine and guanine with various linkers. The 
distribution of scores for the complete pharmacophore library is shown, with the score of 
the Msi1 pharmacophore indicated (red arrow). These artificial compounds match many 
other pharmacophores better than they match the Msi1 pharmacophore. (C) Application 
of this approach to R12. One pharmacophore from the library have scores comparable to 
that of Msi1; this match is accessed through the conformational flexibilty of R12 (blue 
arrows/boxes). (D) Application of this approach to R13. No pharmacophores from the 
library have scores comparable to that of Msi1; the scores of the off-target matches to 
R12 are now significantly worse (blue arrows), since R13 can no longer access these 
alternate conformations. In all cases the red arrow indicates the score of the hotspot 
pharmacophore derived from the first model in the Msi1/RNA NMR ensemble, and the 
red bar indicates the range of scores spanned by pharmacophores extracted from the 










Figure 4.11: Computational prediction of potential off-target interactions. We 
screened each conformer of a given ligand against a large set of hotspot pharmacophores 
derived from other protein-RNA complexes, as described in Figure 4.10. (A) 

























Figure 4.12: Detailed geometry of hotspot pharmacophore delivers selectivity. We 
identified another adenine-guanine derived pharmacophore from another RRM domain 
(Tra2-β1, PDB ID: 2KXN), and examined the similarity between this alternative 
pharmacophore and R13. (A) The superposition of Msi1 RBD1 and the RRM domain 
from Tra2-β1. Protein and adenine-guanine nucleobases from Msi1 complex are shown in 
different shades of gray, while they are in different shades of yellow for Tra2-β1 
complex. (B) The superposition of R13 (cyan stick) to pharmacophore of Tra2-β1 
(magenta stick) demonstrates the lack of similarity between them. An obvious steric clash 










The ability to rationally design selective inhibitors of RNA-binding proteins in a 
robust and general way will enable development of new tool compounds to help elucidate 
cellular processes mediated by these interactions. Naturally-occurring examples have 
shown that proteins can mimic certain structural features of RNAs (183, 184); here, we 
instead encode a key RNA epitope on a small-molecule scaffold. We demonstrate the 
application of our approach using Musashi-1, leading to a novel class of inhibitors that 
disrupt the RNA-binding activity of this tumor-promoting protein. By using the hotspot 
pharmacophore as a template for ligand-based screening, our approach circumvents the 
challenge of explicitly designing de novo interactions against a relatively flat and polar 
protein surface. 
The major advantages of this mimicry approach are its generality and simplicity. 
In this first application of the RNA mimicry approach, we elected to restrict our initial 
screening to commercially available compounds. Though convenient, none of the 
resulting hit compounds provided complete recapitulation of the desired hotspot 
interactions. Of three compounds that each matched three of the pharmacophore’s polar 
groups, only one compound (R12) complemented the protein surface without steric 
clashes. In light of the fact that this compound provided a starting point for new inhibitors 
of Msi1, and thus validated the computational method, in future it will be worthwhile to 
explore chemical space more extensively in search of hits that more effectively mimic the 
desired hotspot pharmacophore. A computational screening platform was recently 
described that uses multi-component reaction chemistry (185) to build a virtual library 
containing tens of millions of novel compounds that can be readily accessed through 
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proven “one-step, one-pot” reactions (42). While this strategy was originally used to 
construct a library of compounds that resemble collections of amino acid sidechains, it 
can be adapted to include privileged moieties that mimic patterns of hydrogen bond 
donors and acceptors in protein-RNA complexes, connected with rigid chemical linkers. 
By expanding the space of available compounds through this combinatorial strategy, and 
integrating computational screening with chemical synthesis, we envision discovery of 
compounds that more accurately match the target hotspot pharmacophores and thus 
exhibit improved potency prior to optimization. 
The design of R12-derived compounds active against the Msi1 / NUMB mRNA 
interaction highlights the simplicity and robustness of the “hotspot mimicry” method, and 
also validates the “druggability” of this protein surface. We expect that the generality of 
this design strategy will allow it to be applied broadly in future, to develop inhibitors of 
RNA-binding proteins as chemical probes and potentially as starting points for 









Chapter V.  
Discussion and Future Steps 
The overall objective of this thesis is to evaluate and develop structure-based 
strategies to modulate protein function. Within this goal, I have demonstrated the general 
designability of  “chemical rescue of structure”, a design strategy to achieve functional 
activation developed by our laboratory. Furthermore, I explored the feasibility of 
extending this approach to a more general setting. Towards the inhibition of protein 
function, I contributed to the development of a “hotspot mimicry” strategy to target 
RNA-binding proteins, and discovered novel compounds targeting the Msi1-1 / NUMB 
mRNA complex. The findings from these projects exhibit successful examples for both 
chemical rescue and hotspot mimicry approaches, demonstrate their general applicability, 
and provide valuable guidelines for the future applications of these approaches. 
Underlying Mechanism of Chemical Rescue of Structure and Hotspot Mimicry 
The fundamental principle underlying both chemical rescue and hotspot mimicry 
approaches is the exploitation of energetic contributions by buried hydrophobic moieties 
in protein structures and macromolecular interactions. From a thermodynamic standpoint, 
the desolvation of hydrophobic chemical groups, i.e. the hydrophobic effect, is the 
dominant driving force in protein folding and interactions (186). So structural 
manipulations involving these hydrophobic elements naturally become the starting points 
for developing rational approaches to modulate protein function. 
Chemical rescue of structure deactivates protein function by deleting the 
sidechain of a buried tryptophan residue, which creates a cavity in the hydrophobic core 
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of protein structure. This removal of hydrophobic moieties decreases the free energy of 
protein folding and leads to a wide variety of structural consequences, ranging from 
discrete conformational changes to local/global unfolding. The hydrophobic packing of 
exogenous indole compensates for the loss of hydrophobicity and restores the native 
protein structure. Analogous processes are also frequently observed in nature: 
hydrophobic packing upon the binding of small molecule also leads to a similar range of 
mechanisms to relay ligand binding to protein function in naturally-occurring systems 
(81). 
The hotspot mimicry approach demonstrates and benefits from the deeply buried 
residues, i.e. hotspots, in protein-RNA interactions. The similar strategy has been 
extensively studied in protein-protein interactions. Seminal work by Jim Wells’ group 
demonstrated the uneven distribution of binding free energies in protein-protein interface 
via alanine scanning (38, 187), and proposed the idea of mimicking the small cluster of 
key residues to design small molecule inhibitors (11, 41). The probing of protein-RNA 
interface via abasic RNA oligos is analogous to the usage of alanine scanning in protein-
protein interactions, and its finding directly establishes the major contribution from the 
hydrophobic effects of buried nucleobases to the free energy of binding. This is the first 
definitive example proving the existence of hotspot residues on RNA molecules. The 
successful usage of these nucleobases as pharmacophore in ligand-based screening 
further supports the druggability of RNA-binding protein surface. 
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Generality of Chemical Rescue of Structure and Hotspot Mimicry 
The design strategies of both chemical rescue of structure and hotspot mimicry 
rely on straightforward usages of hydrophobic effect, and therefore possess excellent 
applicability to other protein scaffolds. 
Chemical rescue of structure can be achieved indirectly by the control of protein 
stability via small molecule binding. This observation immediately expands the 
applicability of the approach: future applications only involve the identification of cavity-
forming mutations that inactivate the protein; the detailed mechanism, however, need not 
be explicitly considered. We have already demonstrated the additional application of 
chemical rescue of structure to GFP and some essential proteins in E.coli, and expect 
more future constructions of protein switches via this approach. 
Chemical rescue of structure demonstrates a wide range of activation mechanisms 
similar to naturally occurring systems. In nature, specific mechanism possesses distinct 
advantages to satisfy different functional requirements, such as kinetics, sensitivity, and 
dynamic range (133, 138, 188). This observation suggests that it is possible to engineer 
desired mechanism into protein scaffolds through careful evaluation of protein structure 
and stability, which will in turn confer the associated advantages that meet to the unique 
criteria presented in specific biological applications. 
Chemical rescue of structure is not limited solely to tryptophan-to-glycine 
mutation and indole rescue. The exploration with ChxR illustrates the feasibility of 
mutating a constellation of atoms from multiple buried residues and rescuing the function 
by more complex small molecules mimicking the three-dimensional structure of the 
missing structural elements. This extension further expands the versatility of the 
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approach: it allows the application to, in principle, all protein hosts, even the ones lacking 
buried tryptophan residues; it also enables the construction of selective sensor proteins to 
a given small molecule by carefully selecting mutations to match the 3D structure of that 
compound (discussed more in the following sections). In addition, the increased 
hydrophobicity of these larger small molecules provides more favorable binding affinity 
and, when applying to living cells, likely improves the membrane permeability. 
The hotspot mimicry approach can, in principle, be applied to any protein-RNA 
interaction that utilizes base stacking. This hydrophobic stacking between nucelobases 
and aromatic amino acids is a predominant mechanism used by the majority of naturally 
occurring RNA-binding domains, including RNA recognition motif (RRM), Zinc finger 
and KH domain (177). I applied the hotspot mimicry approach to a RRM domain, as it is 
one of the most abundant protein domains in eukaryotes and associated with many 
important cellular processes (176). The hotspot mimicry approach sifted out two buried 
nucleobases, whose major contribution to binding free energy was experimentally 
confirmed. The interaction pattern involving a pair of adjacent nucleobases and three 
outward-facing aromatic amino acids is a common feature to all RRMs, but the precise 
geometry of the dinucleotide in complex with the RRM can differ very drastically across 
members of this family. This finding not only corroborates the robustness of our 
computational framework, but also demonstrates the advantages of applying hotspot 
mimicry approach to RRMs: we can effectively identify small molecule inhibitors for 
other members of RRMs via a similar way, and these compounds will most likely be 
selective to the intended targets, as they mimic the 3D geometry of the dinucleotides, not 
merely the 2D chemical properties. Via homology modeling, the conserved interaction 
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pattern of RRMs can be further utilized to generalize the hotspot mimicry approach to 
RRMs that lack the holo-structure with cognate RNAs. 
Future steps of activation via chemical rescue 
 The possibility of employing chemical rescue of structure using multiple 
mutations can be utilized in the converse manner to achieve the design of selective sensor 
proteins to certain small molecules, especially the ones for which no naturally-occurring 
protein binding partner is known. To discover protein structures suitable of harboring the 
small-molecule binding site, we can perform the chemical rescue of structure in reverse. 
The procedure starts by partitioning the structure of a given small molecule into in 
substructures corresponding to the deleted chemical moieties from any “large-to-small” 
single point mutation. If such partition is feasible, we can examine all protein structures 
to identify protein hosts that have the corresponding “large” amino acids in close 
proximity, and build a library containing these constellations of the deleted chemical 
moieties from all suitable proteins. This library can then be screened using the small 
molecule of interest as the template for constellations that mimic the structural geometry 
and chemical property of the small molecule. The corresponding protein host can then be 
mutated to harbor a de novo binding site specific for that small molecule. In order to 
achieve sensing activity, we can either solely use catalytic domains in the screening 
process, or fuse the designed domain with a catalytic domain and resort to conventional 
design strategies, such as domain insertion, to achieve the coupling between small 
molecule binding and catalytic activity. 
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Future steps of inhibition via hotspot mimicry 
The computational examination of selectivity demonstrates that small molecule 
inhibitors identified via hotspot mimicry approach are generally specific to the intended 
target. The procedure, however, did identify potential off-target proteins. It will greatly 
corroborate the robustness of the computational procedure if we can experimentally 
demonstrate that the predicted off-target proteins can indeed bind to the corresponding 
small molecule. The ability of reliably predicting the selectivity of a hotspot 
pharmacophore will enable the discovery of most unique hotspot pharmacophore or a 
group of isolated but closely related pharmacophores: we can cluster the hotspot 
pharmacophores from available structures of disease-related RBPs basing on 3D 
similarity, and identify the most isolated pharmacophore, or a isolated cluster of 
pharmacophores. The former study enables the development of highly selective drugs by 
targeting the most unique hotspot pharmacophore; the latter help the identification of 
small molecules that concomitantly inhibit multiple protein targets. 
One limitation of the examination of selectivity is that it only considers the static 
structure of protein-RNA complexes, which may result in an overestimation of the 
selectivity. The inclusion of twenty Msi-1 pharmacophores obtained from NMR structure 
suggests that the selectivity of a hotspot pharmacophore may not be sensitivity to the 
dynamic range observed in NMR. However, thorough studies are required to draw more 
definitive conclusions. Computational tools have been recently developed and are 
available in Rosetta software suite to allow effective modeling of the dynamic movement 
in protein-RNA complexes, and enable the generation of dynamic ensemble of protein-
RNA complexes from a static structure. Including these dynamic structures in the 
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selectivity examination provides a more rigorous evaluation of potential off-target 
binders. 
In the application to Msi-1, I am aware of the low hit rate and the relative weak 
bindings of the hit compounds, and we can improve the methodology via various 
strategies. As the first test, we elected to restrict the virtual screening to commercially 
available compounds in the “Drugs-Now” database. Though convenient, none of the 
resulting compounds completely recapitulates the intended hotspot interactions. 
Furthermore, molecules in the “Drugs-Now” database are selected following the 
Lipinski’s “rule of five” criteria. It is shown, however, that the inhibitors for non-
traditional targets may violate these criteria (189). These observations strongly suggest 
the need of a larger and focused small molecule library in future applications to enable a 
more extensive exploration of the chemical space in search of hits that can more 
effectively mimic that desired hotspot pharmacophore. One method of constructing such 
virtual libraries is to include the compounds obtainable from the multi-component 
reactions (42). While this strategy was originally used to construct a library of 
compounds that resemble collections of amino acid sidechains, it can be adapted to 
include privileged moieties that mimic patterns of hydrogen bond donors and acceptors in 
protein-RNA complexes, connected with rigid chemical linkers. By expanding the space 
of available compounds through this combinatorial strategy, and integrating 
computational screening with chemical synthesis, we envision discovery of compounds 
that more accurately match the target hotspot pharmacophores and thus exhibit improved 
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